<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d9" for="edge" attr.name="context" attr.type="string" />
  <key id="d8" for="edge" attr.name="type" attr.type="string" />
  <key id="d7" for="node" attr.name="canonical_name" attr.type="string" />
  <key id="d6" for="node" attr.name="name" attr.type="string" />
  <key id="d5" for="node" attr.name="entity_type" attr.type="string" />
  <key id="d4" for="node" attr.name="paper_id" attr.type="string" />
  <key id="d3" for="node" attr.name="statement" attr.type="string" />
  <key id="d2" for="node" attr.name="year" attr.type="long" />
  <key id="d1" for="node" attr.name="content" attr.type="string" />
  <key id="d0" for="node" attr.name="type" attr.type="string" />
  <graph edgedefault="directed">
    <node id="PDF_13">
      <data key="d0">Paper</data>
      <data key="d1">Efficacy and Safety of Perindopril in Patients with Essential Hypertension

DOI: 10.5455/msm.2020.32.4-9
Received: JAN 09 2020; Accepted: MAR 02, 2020
© 2020 Enisa Hodzic, Ehlimana Pecar, Alen Dzubur, Elnur Smajic, Zorica Hondo, Daniela Delic, Edhem Rustempasic

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/4.0/) which permits unrestricted non-commercial use, distribution, and repr</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_13_Result_-6969795018367777339">
      <data key="d0">Result</data>
      <data key="d1">In the great majority of the study patients (more than 96%) perindopril was effective as monotherapy, achieving a significant reduction in both systolic and diastolic blood pressure, and in three-quarters of the study patients it normalized both systolic and diastolic blood pressure.</data>
      <data key="d3">In the great majority of the study patients (more than 96%) perindopril was effective as monotherapy, achieving a significant reduction in both systolic and diastolic blood pressure, and in three-quarters of the study patients it normalized both systolic and diastolic blood pressure.</data>
      <data key="d4">PDF_13</data>
    </node>
    <node id="Compound_PERINDOPRIL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">PERINDOPRIL</data>
      <data key="d7">Perindopril</data>
    </node>
    <node id="PDF_13_Result_-1840300504446391296">
      <data key="d0">Result</data>
      <data key="d1">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
      <data key="d3">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
      <data key="d4">PDF_13</data>
    </node>
    <node id="PDF_13_Conclusion_2175378491144090458">
      <data key="d0">Conclusion</data>
      <data key="d1">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
      <data key="d3">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
      <data key="d4">PDF_13</data>
    </node>
    <node id="Disease_ESSENTIAL HYPERTENSION">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">ESSENTIAL HYPERTENSION</data>
      <data key="d7">Essential hypertension</data>
    </node>
    <node id="PDF_16">
      <data key="d0">Paper</data>
      <data key="d1">RESEARCH
Effect of perindopril on physical function in elderly people
with functional impairment: a randomized controlled trial
Deepa Sumukadas MBBS MD, Miles D. Witham MBChB PhD, Allan D. Struthers MBChB MD,
Marion E.T. McMurdo MBChB MD
8
See related article page 891
ABSTRACT
Background: Physical function and exercise capacity decline
with age and are a major source of disability in older people.
Recent evidence suggests a potential role for the renin-
angiotensin system in modulating muscle fu</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_16_Result_-110396406922382148">
      <data key="d0">Result</data>
      <data key="d1">The mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group (mean between-group difference 31.4 m, 95% confidence interval [CI] 10.8 to 51.9 m; p = 0.003).</data>
      <data key="d3">The mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group (mean between-group difference 31.4 m, 95% confidence interval [CI] 10.8 to 51.9 m; p = 0.003).</data>
      <data key="d4">PDF_16</data>
    </node>
    <node id="PDF_16_Result_-3094613332956725653">
      <data key="d0">Result</data>
      <data key="d1">There was a significant impact on health-related quality of life: although the mean score for part 1 of the EQ-5D questionnaire deteriorated over time in the placebo group, quality of life was maintained in the perindopril group, for a between-group difference of 0.09 (p = 0.046).</data>
      <data key="d3">There was a significant impact on health-related quality of life: although the mean score for part 1 of the EQ-5D questionnaire deteriorated over time in the placebo group, quality of life was maintained in the perindopril group, for a between-group difference of 0.09 (p = 0.046).</data>
      <data key="d4">PDF_16</data>
    </node>
    <node id="PDF_16_Conclusion_660614483491161994">
      <data key="d0">Conclusion</data>
      <data key="d1">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
      <data key="d3">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
      <data key="d4">PDF_16</data>
    </node>
    <node id="PDF_15">
      <data key="d0">Paper</data>
      <data key="d1">ORIGINAL ARTICLE
Journal of Human Hypertension (2000) 14, 321-325
© 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00
www.nature.com/jhh
Antihypertensive efficacy of the ACE-
inhibitor perindopril in the elderly
FHH Leenen¹, J Tanner² and CF McNally³
1University of Ottawa Heart Institute, Ottawa, Ontario, Canada; 2General Practice Research Group,
Toronto, Ontario, Canada; ³Clinical Research Partners, Mount Laurel, NJ, USA

To assess the antihypertensive efficacy of the angiot</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_15_Method_7208700364633966312">
      <data key="d0">Method</data>
      <data key="d1">The study used a multicentre, randomised, placebo-controlled, parallel group design to evaluate the antihypertensive efficacy of perindopril in an elderly hypertensive population.</data>
      <data key="d3">The study used a multicentre, randomised, placebo-controlled, parallel group design to evaluate the antihypertensive efficacy of perindopril in an elderly hypertensive population.</data>
      <data key="d4">PDF_15</data>
    </node>
    <node id="PDF_15_Result_6873332449068391565">
      <data key="d0">Result</data>
      <data key="d1">In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P &lt; 0.01 vs placebo).</data>
      <data key="d3">In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P &lt; 0.01 vs placebo).</data>
      <data key="d4">PDF_15</data>
    </node>
    <node id="PDF_15_Result_5078306612820016528">
      <data key="d0">Result</data>
      <data key="d1">Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg.</data>
      <data key="d3">Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg.</data>
      <data key="d4">PDF_15</data>
    </node>
    <node id="PDF_15_Result_696242867850604664">
      <data key="d0">Result</data>
      <data key="d1">Successful treatment, defined as supine diastolic BP &lt;90 mm Hg or &gt;10 mm Hg decrease from baseline at end of treatment was significantly (P = 0.014) higher on perindopril (60%) compared to placebo (44%).</data>
      <data key="d3">Successful treatment, defined as supine diastolic BP &lt;90 mm Hg or &gt;10 mm Hg decrease from baseline at end of treatment was significantly (P = 0.014) higher on perindopril (60%) compared to placebo (44%).</data>
      <data key="d4">PDF_15</data>
    </node>
    <node id="PDF_15_Conclusion_-4354921419621582139">
      <data key="d0">Conclusion</data>
      <data key="d1">The present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
      <data key="d3">The present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
      <data key="d4">PDF_15</data>
    </node>
    <node id="PDF_8">
      <data key="d0">Paper</data>
      <data key="d1">ELSEVIER
DIABETES RESEARCH AND CLINICAL PRACTICE 93 (2011) 410-420

Contents lists available at ScienceDirect

Diabetes Research
and Clinical Practice

journal homepage: www.elsevier.com/locate/diabres

International
Diabetes
Federation

DIABETES
RESEARCH AND
CLINICAL PRACTICE

Peptide complex containing GLP-1 exhibited long-acting
properties in the treatment of type 2 diabetes
Xuemin Zheng a,1, Ying Lib,1, Xin Li, Lida Tanga, Weiren Xud, Min Gong b,d,*
a Department of Pharmaceutical Analysis, T</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_8_Hypothesis_3044518278249807850">
      <data key="d0">Hypothesis</data>
      <data key="d1">The GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
      <data key="d3">The GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
      <data key="d4">PDF_8</data>
    </node>
    <node id="Protein_GLP-1">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">GLP-1</data>
      <data key="d7">GLP-1</data>
    </node>
    <node id="Disease_TYPE 2 DIABETES MELLITUS">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">TYPE 2 DIABETES MELLITUS</data>
      <data key="d7">type 2 diabetes mellitus</data>
    </node>
    <node id="PDF_8_Method_1090791868839956195">
      <data key="d0">Method</data>
      <data key="d1">The stability of the GLP-1/peptide 1 complex was investigated, and the physiological functions of the GLP-1/peptide 1 complex were compared to those of exenatide and liraglutide in animals.</data>
      <data key="d3">The stability of the GLP-1/peptide 1 complex was investigated, and the physiological functions of the GLP-1/peptide 1 complex were compared to those of exenatide and liraglutide in animals.</data>
      <data key="d4">PDF_8</data>
    </node>
    <node id="Compound_EXENATIDE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">EXENATIDE</data>
      <data key="d7">exenatide</data>
    </node>
    <node id="Compound_LIRAGLUTIDE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">LIRAGLUTIDE</data>
      <data key="d7">liraglutide</data>
    </node>
    <node id="PDF_8_Result_7006409746140902161">
      <data key="d0">Result</data>
      <data key="d1">The GLP-1/peptide 1 complex remarkably raised the half-life of GLP-1 in vivo and showed better glucose tolerance and higher HbA1c reduction than exenatide and liraglutide in rodents.</data>
      <data key="d3">The GLP-1/peptide 1 complex remarkably raised the half-life of GLP-1 in vivo and showed better glucose tolerance and higher HbA1c reduction than exenatide and liraglutide in rodents.</data>
      <data key="d4">PDF_8</data>
    </node>
    <node id="PDF_19">
      <data key="d0">Paper</data>
      <data key="d1">www.nature.com/scientificreports
scientific reports
OPEN A pro-oxidant combination
of resveratrol and copper
down-regulates multiple
biological hallmarks of ageing
and neurodegeneration in mice
Kavita Pal1,2,3, Gorantla V. Raghuram1,2,3, Jenevieve Dsouza¹,2, Sushma Shinde1,2,
Vishalkumar Jadhav¹,2, Alfina Shaikh¹,2, Bhagyeshri Rane¹,2, Harshali Tandel 1,2,
Dipali Kondhalkar¹,2, Shahid Chaudhary¹,2 &amp; Indraneel Mittra (1,2
Check for updates
Billions of cells die in the body every day, and cell-fre</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_19_Hypothesis_-2602979087861542700">
      <data key="d0">Hypothesis</data>
      <data key="d1">lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs</data>
      <data key="d3">lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs</data>
      <data key="d4">PDF_19</data>
    </node>
    <node id="Compound_CFCHPS">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">CFCHPS</data>
      <data key="d7">cfChPs</data>
    </node>
    <node id="PDF_19_Method_-4736383758653828058">
      <data key="d0">Method</data>
      <data key="d1">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months.</data>
      <data key="d3">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu. The control ageing group was given water by oral gavage twice daily for 12 months. Animals of both groups were sacrificed at age 22 months.</data>
      <data key="d4">PDF_19</data>
    </node>
    <node id="PDF_19_Result_-1189977786821166082">
      <data key="d0">Result</data>
      <data key="d1">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction.</data>
      <data key="d3">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction.</data>
      <data key="d4">PDF_19</data>
    </node>
    <node id="Gene_DNA">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">DNA</data>
      <data key="d7">DNA</data>
    </node>
    <node id="PDF_19_Result_-1548407765133182630">
      <data key="d0">Result</data>
      <data key="d1">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein.</data>
      <data key="d3">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein.</data>
      <data key="d4">PDF_19</data>
    </node>
    <node id="PDF_19_Conclusion_9036677103515943065">
      <data key="d0">Conclusion</data>
      <data key="d1">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
      <data key="d3">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
      <data key="d4">PDF_19</data>
    </node>
    <node id="PDF_17">
      <data key="d0">Paper</data>
      <data key="d1">Here is the complete OCR text from the scientific PDF, as you requested.

373
CARDIOVASCULAR MEDICINE
Perindopril improves six minute walking distance in older
patients with left ventricular systolic dysfunction:
a randomised double blind placebo controlled trial
SD Hutcheon, N D Gillespie, I K Crombie, A D Struthers, MET McMurdo
Heart 2002;88:373-377
Objective: To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six
minute walking distance and quality of life i</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_17_Result_-5583964824094673079">
      <data key="d0">Result</data>
      <data key="d1">In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p &lt; 0.001).</data>
      <data key="d3">In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p &lt; 0.001).</data>
      <data key="d4">PDF_17</data>
    </node>
    <node id="PDF_17_Conclusion_-8096456597440705116">
      <data key="d0">Conclusion</data>
      <data key="d1">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
      <data key="d3">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
      <data key="d4">PDF_17</data>
    </node>
    <node id="PDF_17_Result_2918214787836327464">
      <data key="d0">Result</data>
      <data key="d1">Patients randomly assigned to perindopril significantly improved their mean walking distance compared with those in the placebo group (p &lt; 0.001) with a mean increase of 37 m in the mean walking distance at 10 weeks.</data>
      <data key="d3">Patients randomly assigned to perindopril significantly improved their mean walking distance compared with those in the placebo group (p &lt; 0.001) with a mean increase of 37 m in the mean walking distance at 10 weeks.</data>
      <data key="d4">PDF_17</data>
    </node>
    <node id="PDF_17_Result_5593485977643258687">
      <data key="d0">Result</data>
      <data key="d1">Perindopril improved the walking distance in both the less symptomatic (NYHA I or II) and the more symptomatic patients (NYHA III or IV).</data>
      <data key="d3">Perindopril improved the walking distance in both the less symptomatic (NYHA I or II) and the more symptomatic patients (NYHA III or IV).</data>
      <data key="d4">PDF_17</data>
    </node>
    <node id="PDF_17_Conclusion_-886874052167900569">
      <data key="d0">Conclusion</data>
      <data key="d1">This study provides a powerful evidence base to justify the widespread use of ACE inhibitors even in very old patients with left ventricular systolic dysfunction.</data>
      <data key="d3">This study provides a powerful evidence base to justify the widespread use of ACE inhibitors even in very old patients with left ventricular systolic dysfunction.</data>
      <data key="d4">PDF_17</data>
    </node>
    <node id="Compound_ACE INHIBITORS">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">ACE INHIBITORS</data>
      <data key="d7">ACE inhibitors</data>
    </node>
    <node id="PDF_1">
      <data key="d0">Paper</data>
      <data key="d1">nature metabolism
Letter
a
https://doi.org/10.1038/s42255-023-00943-3
Randomized open-label trial of semaglutide
and dapagliflozin in patients with type 2
diabetes of different pathophysiology
Received: 9 May 2023
A list of authors and their affiliations appears at the end of the paper
Accepted: 8 November 2023
Published online: 4 January 2024
Check for updates
The limited understanding of the heterogeneity in the treatment response
to antidiabetic drugs contributes to metabolic deterioration an</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_1_Result_3142213223919009091">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
      <data key="d3">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
      <data key="d4">PDF_1</data>
    </node>
    <node id="Protein_HBA1C">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">HBA1C</data>
      <data key="d7">HbA1c</data>
    </node>
    <node id="Compound_SEMAGLUTIDE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">SEMAGLUTIDE</data>
      <data key="d7">Semaglutide</data>
    </node>
    <node id="Compound_DAPAGLIFLOZIN">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">DAPAGLIFLOZIN</data>
      <data key="d7">dapagliflozin</data>
    </node>
    <node id="Disease_SIDD">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">SIDD</data>
      <data key="d7">SIDD</data>
    </node>
    <node id="PDF_1_Result_4139653914714409106">
      <data key="d0">Result</data>
      <data key="d1">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin</data>
      <data key="d3">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin</data>
      <data key="d4">PDF_1</data>
    </node>
    <node id="PDF_1_Result_8944576178123360759">
      <data key="d0">Result</data>
      <data key="d1">dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment</data>
      <data key="d3">dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment</data>
      <data key="d4">PDF_1</data>
    </node>
    <node id="Process_INSULIN RESISTANCE">
      <data key="d0">Entity</data>
      <data key="d5">Process</data>
      <data key="d6">INSULIN RESISTANCE</data>
      <data key="d7">insulin resistance</data>
    </node>
    <node id="PDF_1_Result_8734249471022747097">
      <data key="d0">Result</data>
      <data key="d1">dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD</data>
      <data key="d3">dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD</data>
      <data key="d4">PDF_1</data>
    </node>
    <node id="Disease_SIRD">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">SIRD</data>
      <data key="d7">SIRD</data>
    </node>
    <node id="PDF_1_Result_3939344856950814862">
      <data key="d0">Result</data>
      <data key="d1">semaglutide resulted in a larger improvement in patient-reported treatment satisfaction compared with dapagliflozin, particularly in the SIDD group</data>
      <data key="d3">semaglutide resulted in a larger improvement in patient-reported treatment satisfaction compared with dapagliflozin, particularly in the SIDD group</data>
      <data key="d4">PDF_1</data>
    </node>
    <node id="PDF_1_Result_7134815922756028491">
      <data key="d0">Result</data>
      <data key="d1">continuous pathophysiological variables can predict the likely treatment response to these common drugs and provide more information than stratified subgroups.</data>
      <data key="d3">continuous pathophysiological variables can predict the likely treatment response to these common drugs and provide more information than stratified subgroups.</data>
      <data key="d4">PDF_1</data>
    </node>
    <node id="PDF_20">
      <data key="d0">Paper</data>
      <data key="d1">OPEN
SUBJECT AREAS:
DRUG DEVELOPMENT
NATURAL PRODUCTS
Received
2 September 2014
Accepted
5 January 2015
Published
28 January 2015
Correspondence and
requests for materials
should be addressed to
A.K.S. (Shetty@
medicine.tamhsc.edu)
* These authors
contributed equally to
this work.
† Current address:
Department of
Radiation Oncology,
Univ California Irvine.
Resveratrol Prevents Age-Related
Memory and Mood Dysfunction with
Increased Hippocampal Neurogenesis
and Microvasculature, and Reduced
Glial </data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_20_Hypothesis_5697665869451186234">
      <data key="d0">Hypothesis</data>
      <data key="d1">resveratrol may preserve cognitive and mood function in old age by mitigating age-related changes in the hippocampus</data>
      <data key="d3">resveratrol may preserve cognitive and mood function in old age by mitigating age-related changes in the hippocampus</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="Compound_RESVERATROL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">RESVERATROL</data>
      <data key="d7">Resveratrol</data>
    </node>
    <node id="PDF_20_Method_-1807004228531522170">
      <data key="d0">Method</data>
      <data key="d1">examined the efficacy of resveratrol for counteracting age-related memory and mood impairments and the associated detrimental changes in the hippocampus in male F344 rats</data>
      <data key="d3">examined the efficacy of resveratrol for counteracting age-related memory and mood impairments and the associated detrimental changes in the hippocampus in male F344 rats</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_5355102210480636028">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment in late middle age improved ability for spatial learning and spatial memory formation at an advanced age</data>
      <data key="d3">RESV treatment in late middle age improved ability for spatial learning and spatial memory formation at an advanced age</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_8938251966814938440">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment improved mood function in aged rats</data>
      <data key="d3">RESV treatment improved mood function in aged rats</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_-7406637995227342214">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats</data>
      <data key="d3">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_-3492516078220279717">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods</data>
      <data key="d3">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_-5523756741762429381">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment enhanced microvasculature in the hippocampus of aged rats</data>
      <data key="d3">RESV treatment enhanced microvasculature in the hippocampus of aged rats</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_889410764312178502">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment reduced the hypertrophy of astrocytes in aged rats</data>
      <data key="d3">RESV treatment reduced the hypertrophy of astrocytes in aged rats</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Result_-7866815614096464297">
      <data key="d0">Result</data>
      <data key="d1">RESV treatment reduced activation of microglia in aged rats</data>
      <data key="d3">RESV treatment reduced activation of microglia in aged rats</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_20_Conclusion_-8909461333127802831">
      <data key="d0">Conclusion</data>
      <data key="d1">RESV treatment in late middle age can positively modulate the structure and function of the aged hippocampus</data>
      <data key="d3">RESV treatment in late middle age can positively modulate the structure and function of the aged hippocampus</data>
      <data key="d4">PDF_20</data>
    </node>
    <node id="PDF_6">
      <data key="d0">Paper</data>
      <data key="d1">nature medicine
a
Article
https://doi.org/10.1038/s41591-024-03463-z
Subcutaneous weekly semaglutide with
automated insulin delivery in type 1 diabetes:
a double-blind, randomized, crossover trial
Received: 12 August 2024
Accepted: 11 December 2024
Published online: 10 January 2025
Check for updates
Melissa-Rosina Pasqua 1,2,3 Michael A. Tsoukas 1,2,3, Alessandra Kobayati 2,3,
Wedyan Aboznadah¹4, Adnan Jafar &amp; Ahmad Haidar 1,2,3,5
Efforts to improve glycemic control in type 1 diabetes are ongoin</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_6_Result_1509227847411498697">
      <data key="d0">Result</data>
      <data key="d1">Compared to placebo, semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol 1¯¹ (P = 0.19) or below 3.0 mmol l¯¹ (P = 0.65).</data>
      <data key="d3">Compared to placebo, semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006), without increasing the time spent below 3.9 mmol 1¯¹ (P = 0.19) or below 3.0 mmol l¯¹ (P = 0.65).</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_6_Conclusion_-8089193946421374005">
      <data key="d0">Conclusion</data>
      <data key="d1">We conclude that semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
      <data key="d3">We conclude that semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_6_Result_-5221652143066512179">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
      <data key="d3">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_6_Result_685452967745399653">
      <data key="d0">Result</data>
      <data key="d1">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo (P&lt;0.001; Table 3), constituting a -5.1% (3.0) relative change from baseline.</data>
      <data key="d3">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo (P&lt;0.001; Table 3), constituting a -5.1% (3.0) relative change from baseline.</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_6_Result_-6785829855875291712">
      <data key="d0">Result</data>
      <data key="d1">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
      <data key="d3">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_6_Result_-934001866393829912">
      <data key="d0">Result</data>
      <data key="d1">Daily carbohydrate intake (as entered into the participants' bolus calculator) was also reduced by 36 g [-55, -15] with semaglutide compared to placebo (P&lt;0.001).</data>
      <data key="d3">Daily carbohydrate intake (as entered into the participants' bolus calculator) was also reduced by 36 g [-55, -15] with semaglutide compared to placebo (P&lt;0.001).</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_6_Result_4648188858690542777">
      <data key="d0">Result</data>
      <data key="d1">The reduction in weight was correlated with the improvements in time in range (Pearson p = 0.50, P = 0.015) and HbA1c (Pearson p = 0.43, P = 0.04; Supplementary Table 8 and Extended Data Fig. 2), that is, those who had the highest weight reduction tended to have the most glycemic benefits.</data>
      <data key="d3">The reduction in weight was correlated with the improvements in time in range (Pearson p = 0.50, P = 0.015) and HbA1c (Pearson p = 0.43, P = 0.04; Supplementary Table 8 and Extended Data Fig. 2), that is, those who had the highest weight reduction tended to have the most glycemic benefits.</data>
      <data key="d4">PDF_6</data>
    </node>
    <node id="PDF_9">
      <data key="d0">Paper</data>
      <data key="d1">Here is all the text from the scientific PDF, with the OCR issues corrected as best as possible.

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1
(IDO1) Inhibitors

Ute F. Röhrig,*,† Somi Reddy Majjigapu, *,* Pierre Vogel,*$ Vincent Zoete,*,† and Olivier Michielin*,†,||,$

*Molecular Modeling Group, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland
*Laboratory of Glycochemistry and Asymmetric Synthesis, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Laus</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_9_Hypothesis_1839083106408537623">
      <data key="d0">Hypothesis</data>
      <data key="d1">IDO1 inhibitory activity could be the result of undesirable side reactions instead of selective binding to IDO1.</data>
      <data key="d3">IDO1 inhibitory activity could be the result of undesirable side reactions instead of selective binding to IDO1.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="Protein_IDO1">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">IDO1</data>
      <data key="d7">IDO1</data>
    </node>
    <node id="PDF_9_Method_-8182141859335369411">
      <data key="d0">Method</data>
      <data key="d1">IDO1 inhibition determined using purified ferric IDO1 reduced by ascorbic acid, necessitating methylene blue as electron carrier.</data>
      <data key="d3">IDO1 inhibition determined using purified ferric IDO1 reduced by ascorbic acid, necessitating methylene blue as electron carrier.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Method_-1811185656356958275">
      <data key="d0">Method</data>
      <data key="d1">IDO1 inhibition determined using cytochrome P450 reductase/NADPH and cytochrome b5 as reductants.</data>
      <data key="d3">IDO1 inhibition determined using cytochrome P450 reductase/NADPH and cytochrome b5 as reductants.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Method_4583438222083563541">
      <data key="d0">Method</data>
      <data key="d1">The amount of L-Trp breakdown monitored by HPLC after stopping the enzymatic reaction by acidification and hydrolysis of NFK to kynurenine at 50 °C.</data>
      <data key="d3">The amount of L-Trp breakdown monitored by HPLC after stopping the enzymatic reaction by acidification and hydrolysis of NFK to kynurenine at 50 °C.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="Compound_L-TRP">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">L-TRP</data>
      <data key="d7">L-Trp</data>
    </node>
    <node id="Compound_KYNURENINE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">KYNURENINE</data>
      <data key="d7">kynurenine</data>
    </node>
    <node id="Compound_NFK">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">NFK</data>
      <data key="d7">NFK</data>
    </node>
    <node id="PDF_9_Method_974516171928313980">
      <data key="d0">Method</data>
      <data key="d1">IDO1 inhibitors discovered by natural product screening, structure-based drug design, or in the majority of cases by high throughput screening (HTS).</data>
      <data key="d3">IDO1 inhibitors discovered by natural product screening, structure-based drug design, or in the majority of cases by high throughput screening (HTS).</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Method_-6761575539062862121">
      <data key="d0">Method</data>
      <data key="d1">Cellular mIDO2 inhibition screen of 640 FDA-approved compounds yielded 43 hits that were subsequently also tested on IDO1.</data>
      <data key="d3">Cellular mIDO2 inhibition screen of 640 FDA-approved compounds yielded 43 hits that were subsequently also tested on IDO1.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="Protein_IDO2">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">IDO2</data>
      <data key="d7">IDO2</data>
    </node>
    <node id="PDF_9_Method_-1111586005617789482">
      <data key="d0">Method</data>
      <data key="d1">IDO1 inhibitors discovered via yeast growth assay</data>
      <data key="d3">IDO1 inhibitors discovered via yeast growth assay</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Result_-8646250785302555436">
      <data key="d0">Result</data>
      <data key="d1">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
      <data key="d3">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="Compound_EBSELEN">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">EBSELEN</data>
      <data key="d7">ebselen</data>
    </node>
    <node id="PDF_9_Result_8483513546146417652">
      <data key="d0">Result</data>
      <data key="d1">IDO1 inhibitory properties have been attributed to thousands of compounds according to the scientific and patent literature.</data>
      <data key="d3">IDO1 inhibitory properties have been attributed to thousands of compounds according to the scientific and patent literature.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Result_-76489948366614969">
      <data key="d0">Result</data>
      <data key="d1">Cellular IC50 values much higher than their enzymatic IC50 values for some quinones and iminoquinones.</data>
      <data key="d3">Cellular IC50 values much higher than their enzymatic IC50 values for some quinones and iminoquinones.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Conclusion_4816139841263321359">
      <data key="d0">Conclusion</data>
      <data key="d1">Caution should be used when interpreting docking results, taking into account that protein flexibility and heme interactions could be ill-described within the chosen approach.</data>
      <data key="d3">Caution should be used when interpreting docking results, taking into account that protein flexibility and heme interactions could be ill-described within the chosen approach.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_9_Conclusion_-3030786454116916093">
      <data key="d0">Conclusion</data>
      <data key="d1">The phenylimidazole scaffold provides a promising starting point for the development of IDO1 inhibitors, as its binding mode to the active site is known through X-ray crystallography.</data>
      <data key="d3">The phenylimidazole scaffold provides a promising starting point for the development of IDO1 inhibitors, as its binding mode to the active site is known through X-ray crystallography.</data>
      <data key="d4">PDF_9</data>
    </node>
    <node id="PDF_18">
      <data key="d0">Paper</data>
      <data key="d1">communications biology
Article
a
https://doi.org/10.1038/s42003-024-07387-9
Resveratrol does not mimic the positive
effects of calorie restriction on lifespan in
Microcebus murinus
Fabien Pifferi¹
Jérémy Terrien¹, Julia Marchal¹, Alexandre Dal-Pan¹, Fathia Djelti 1,2,
Martine Perret¹, Jacques Epelbaum¹, Stéphane Blanc³, Jean-Luc Picq¹, Marc Dhenain5,6 &amp;
Fabienne Aujard¹
Check for updates
Resveratrol (RSV), a polyphenol with anti-aging properties affecting metabolism and energy balance,
is consid</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_18_Hypothesis_9079035788419069742">
      <data key="d0">Hypothesis</data>
      <data key="d1">We hypothesize that long-term supplementation with an intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
      <data key="d3">We hypothesize that long-term supplementation with an intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_18_Method_451804169188668694">
      <data key="d0">Method</data>
      <data key="d1">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
      <data key="d3">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="Gene_MICROCEBUS MURINUS">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">MICROCEBUS MURINUS</data>
      <data key="d7">Microcebus murinus</data>
    </node>
    <node id="PDF_18_Result_6138634157418763559">
      <data key="d0">Result</data>
      <data key="d1">RSV supplementation improved cognitive and motor performance at middle age as compared to control (CTL) animals.</data>
      <data key="d3">RSV supplementation improved cognitive and motor performance at middle age as compared to control (CTL) animals.</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_18_Result_169181898259998290">
      <data key="d0">Result</data>
      <data key="d1">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
      <data key="d3">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_18_Result_-5898660160653364919">
      <data key="d0">Result</data>
      <data key="d1">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
      <data key="d3">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_18_Result_8108736170855866172">
      <data key="d0">Result</data>
      <data key="d1">Incidence of age-related pathologies such as cancer and chronic nephritis was not significantly changed by RSV supplementation</data>
      <data key="d3">Incidence of age-related pathologies such as cancer and chronic nephritis was not significantly changed by RSV supplementation</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="Disease_CANCER">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">CANCER</data>
      <data key="d7">cancer</data>
    </node>
    <node id="Disease_NEPHRITIS">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">NEPHRITIS</data>
      <data key="d7">nephritis</data>
    </node>
    <node id="PDF_18_Conclusion_-7700792071022539550">
      <data key="d0">Conclusion</data>
      <data key="d1">long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
      <data key="d3">long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_18_Conclusion_3138895423587022325">
      <data key="d0">Conclusion</data>
      <data key="d1">very long-term RSV supplementation results in health benefits at middle-age in male mouse lemurs, as demonstrated here for motor and cognitive capacities, but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
      <data key="d3">very long-term RSV supplementation results in health benefits at middle-age in male mouse lemurs, as demonstrated here for motor and cognitive capacities, but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_18_Conclusion_-2483027973675422084">
      <data key="d0">Conclusion</data>
      <data key="d1">long-term RSV supplementation does not mimic the lifespan extension provided by chronic CR, and does not reduce either the risk of age-associated diseases or age-associated mortality.</data>
      <data key="d3">long-term RSV supplementation does not mimic the lifespan extension provided by chronic CR, and does not reduce either the risk of age-associated diseases or age-associated mortality.</data>
      <data key="d4">PDF_18</data>
    </node>
    <node id="PDF_2">
      <data key="d0">Paper</data>
      <data key="d1">JCI INSIGHT
RESEARCH ARTICLE
Semaglutide lowers body weight in
rodents via distributed neural pathways
Sanaz Gabery,¹ Casper G. Salinas,¹ Sarah J. Paulsen,¹ Jonas Ahnfelt-Rønne,¹ Tomas Alanentalo,¹ Arian
F. Baquero, Stephen T. Buckley,² Erzsébet Farkas, Csaba Fekete,³ Klaus S. Frederiksen,¹ Wouter
Frederik Johan Hogendorf, Hans Christian C. Helms,² Jacob F. Jeppesen,¹ Linu M. John,¹ Charles
Pyke,¹ Jane Nøhr,¹ Tess T. Lu,¹ Joseph Polex-Wolf,¹ Vincent Prevot, 4 Kirsten Raun,¹ Lotte Simonsen,¹
Gao </data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_2_Hypothesis_-8297886518736926679">
      <data key="d0">Hypothesis</data>
      <data key="d1">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
      <data key="d3">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="Protein_GLP-1R">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">GLP-1R</data>
      <data key="d7">GLP-1R</data>
    </node>
    <node id="PDF_2_Method_-4517108383457012009">
      <data key="d0">Method</data>
      <data key="d1">Diet-induced obese (DIO) mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated.</data>
      <data key="d3">Diet-induced obese (DIO) mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_-4308519927738533622">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
      <data key="d3">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_8453552442843427402">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
      <data key="d3">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_4299364976257756467">
      <data key="d0">Result</data>
      <data key="d1">The reduction in energy intake was driven by decreased chocolate intake with semaglutide treatment compared with vehicle.</data>
      <data key="d3">The reduction in energy intake was driven by decreased chocolate intake with semaglutide treatment compared with vehicle.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_5074024079918988038">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide specifically accesses GLP-1R-positive brain areas following peripheral administration.</data>
      <data key="d3">Semaglutide specifically accesses GLP-1R-positive brain areas following peripheral administration.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_-1674698398303613927">
      <data key="d0">Result</data>
      <data key="d1">GLP-1R expression in rat tissue was detected within tanycytes, neuronal perikarya, and dendrites, with more limited staining in  tanycytes.</data>
      <data key="d3">GLP-1R expression in rat tissue was detected within tanycytes, neuronal perikarya, and dendrites, with more limited staining in  tanycytes.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_7536818821284748040">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide does not interact with endothelial cells of the BBB.</data>
      <data key="d3">Semaglutide does not interact with endothelial cells of the BBB.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Result_-3809630368760752699">
      <data key="d0">Result</data>
      <data key="d1">GLP-1R was coexpressed with CART in the ARH but not in the AP or NTS.</data>
      <data key="d3">GLP-1R was coexpressed with CART in the ARH but not in the AP or NTS.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="Gene_CART">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">CART</data>
      <data key="d7">CART</data>
    </node>
    <node id="PDF_2_Result_-1948915980787463556">
      <data key="d0">Result</data>
      <data key="d1">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours).</data>
      <data key="d3">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours).</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_2_Conclusion_4539983027530505413">
      <data key="d0">Conclusion</data>
      <data key="d1">We suggest semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
      <data key="d3">We suggest semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
      <data key="d4">PDF_2</data>
    </node>
    <node id="PDF_10">
      <data key="d0">Paper</data>
      <data key="d1">Here is the complete text from the scientific PDF:

The Journal of Clinical Investigation
RESEARCH ARTICLE
The arcuate nucleus mediates GLP-1 receptor agonist
liraglutide-dependent weight loss
Anna Secher,¹ Jacob Jelsing,¹ Arian F. Baquero,³ Jacob Hecksher-Sørensen,¹ Michael A. Cowley, Louise S. Dalbøge,2
Gitte Hansen,² Kevin L. Grove, Charles Pyke,¹ Kirsten Raun,¹ Lauge Schäffer,¹ Mads Tang-Christensen,¹ Saurabh Verma,³
Brent M. Witgen,¹ Niels Vrang, 2 and Lotte Bjerre Knudsen¹
'Diabetes Resear</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_10_Hypothesis_-377144521760521173">
      <data key="d0">Hypothesis</data>
      <data key="d1">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
      <data key="d3">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="Gene_POMC">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">POMC</data>
      <data key="d7">POMC</data>
    </node>
    <node id="Process_ARC">
      <data key="d0">Entity</data>
      <data key="d5">Process</data>
      <data key="d6">ARC</data>
      <data key="d7">ARC</data>
    </node>
    <node id="PDF_10_Method_3069679492984245994">
      <data key="d0">Method</data>
      <data key="d1">Peripheral injection of fluorescently labeled liraglutide in mice</data>
      <data key="d3">Peripheral injection of fluorescently labeled liraglutide in mice</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Method_-3886734006662591511">
      <data key="d0">Method</data>
      <data key="d1">Electrophysiological measurements of murine brain slices</data>
      <data key="d3">Electrophysiological measurements of murine brain slices</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Result_-4458030266816943244">
      <data key="d0">Result</data>
      <data key="d1">Liraglutide does not activate GLP-1-producing neurons in the hindbrain.</data>
      <data key="d3">Liraglutide does not activate GLP-1-producing neurons in the hindbrain.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Result_1276167620882736574">
      <data key="d0">Result</data>
      <data key="d1">Liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
      <data key="d3">Liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Result_4145573934341478012">
      <data key="d0">Result</data>
      <data key="d1">Labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
      <data key="d3">Labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Result_8527041239487712763">
      <data key="d0">Result</data>
      <data key="d1">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
      <data key="d3">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Result_-4160943347152761472">
      <data key="d0">Result</data>
      <data key="d1">Liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) in the ARC.</data>
      <data key="d3">Liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) in the ARC.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_10_Result_1933072671520032081">
      <data key="d0">Result</data>
      <data key="d1">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
      <data key="d3">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="Gene_NPY">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">NPY</data>
      <data key="d7">NPY</data>
    </node>
    <node id="Gene_AGRP">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">AGRP</data>
      <data key="d7">AgRP</data>
    </node>
    <node id="Compound_GABA">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">GABA</data>
      <data key="d7">GABA</data>
    </node>
    <node id="PDF_10_Conclusion_-377144521760521173">
      <data key="d0">Conclusion</data>
      <data key="d1">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
      <data key="d3">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
      <data key="d4">PDF_10</data>
    </node>
    <node id="PDF_7">
      <data key="d0">Paper</data>
      <data key="d1">nature medicine
Article
a
https://doi.org/10.1038/s41591-024-03355-2
Proteomic changes upon treatment with
semaglutide in individuals with obesity
Received: 22 March 2024
Accepted: 14 October 2024
Published online: 3 January 2025
Check for updates
Lasse Maretty1,11, Dipender Gill 2,3, Lotte Simonsen, Keng Soh',
Loukas Zagkos2, Michael Galanakis¹5, Jonas Sibbesen¹,
Miquel Triana Iglesias¹, Anna Secher, Dirk Valkenborg,
Jonathan Q. Purnell, Lotte Bjerre Knudsen, Abd A. Tahrani 9,10,13 &amp;
Milan Geyb</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_7_Result_4202519547059753600">
      <data key="d0">Result</data>
      <data key="d1">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment (compared with placebo) in STEP 1 (P &lt;0.05, after Holm-Bonferroni correction for the 7,289 aptamers tested)</data>
      <data key="d3">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment (compared with placebo) in STEP 1 (P &lt;0.05, after Holm-Bonferroni correction for the 7,289 aptamers tested)</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Result_-7151319057790118606">
      <data key="d0">Result</data>
      <data key="d1">In the STEP 2 trial, the relative abundance of 277 protein targets (244 unique proteins) was changed significantly in response to semaglutide treatment relative to placebo</data>
      <data key="d3">In the STEP 2 trial, the relative abundance of 277 protein targets (244 unique proteins) was changed significantly in response to semaglutide treatment relative to placebo</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Result_-1494737022746030875">
      <data key="d0">Result</data>
      <data key="d1">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
      <data key="d3">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="Protein_CRP">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">CRP</data>
      <data key="d7">CRP</data>
    </node>
    <node id="Protein_LEPTIN">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">LEPTIN</data>
      <data key="d7">leptin</data>
    </node>
    <node id="Protein_ADIPONECTIN">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">ADIPONECTIN</data>
      <data key="d7">adiponectin</data>
    </node>
    <node id="Protein_GHRELIN">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">GHRELIN</data>
      <data key="d7">ghrelin</data>
    </node>
    <node id="Protein_IGFBP">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">IGFBP</data>
      <data key="d7">IGFBP</data>
    </node>
    <node id="Protein_GHR">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">GHR</data>
      <data key="d7">GHR</data>
    </node>
    <node id="Protein_NCAM1">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">NCAM1</data>
      <data key="d7">NCAM1</data>
    </node>
    <node id="Protein_UNC5D">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">UNC5D</data>
      <data key="d7">UNC5D</data>
    </node>
    <node id="PDF_7_Result_809844039502751496">
      <data key="d0">Result</data>
      <data key="d1">Protein set analyses found that semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
      <data key="d3">Protein set analyses found that semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="Protein_MTORC1">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">MTORC1</data>
      <data key="d7">MTORC1</data>
    </node>
    <node id="PDF_7_Result_-152863557928388820">
      <data key="d0">Result</data>
      <data key="d1">Adjusting for body weight and HbA1c changes at the end of treatment identified 47 (38 unique proteins) and 15 (14 unique proteins) protein targets significantly altered by semaglutide treatment in STEP 1 and STEP 2, respectively</data>
      <data key="d3">Adjusting for body weight and HbA1c changes at the end of treatment identified 47 (38 unique proteins) and 15 (14 unique proteins) protein targets significantly altered by semaglutide treatment in STEP 1 and STEP 2, respectively</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Result_-7534957547168955468">
      <data key="d0">Result</data>
      <data key="d1">Significantly regulated proteins in this analysis are implicated in diverse biological effects (for example, cardiac stress, inflammation and lipid metabolism) and have previously been found to be increased in CVD or associated with higher CVD risk.</data>
      <data key="d3">Significantly regulated proteins in this analysis are implicated in diverse biological effects (for example, cardiac stress, inflammation and lipid metabolism) and have previously been found to be increased in CVD or associated with higher CVD risk.</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Result_-8234881479684600874">
      <data key="d0">Result</data>
      <data key="d1">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
      <data key="d3">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="Protein_TENASCIN C">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">TENASCIN C</data>
      <data key="d7">tenascin C</data>
    </node>
    <node id="Protein_NT-PROBNP">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">NT-PROBNP</data>
      <data key="d7">NT-proBNP</data>
    </node>
    <node id="Protein_THROMBOSPONDIN 2">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">THROMBOSPONDIN 2</data>
      <data key="d7">thrombospondin 2</data>
    </node>
    <node id="Protein_CD93">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">CD93</data>
      <data key="d7">CD93</data>
    </node>
    <node id="Protein_MSR1">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">MSR1</data>
      <data key="d7">MSR1</data>
    </node>
    <node id="Protein_ANGPT2">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">ANGPT2</data>
      <data key="d7">ANGPT2</data>
    </node>
    <node id="PDF_7_Result_6786663891860836604">
      <data key="d0">Result</data>
      <data key="d1">The STEP 1 signature had a high classification performance (internal nested cross-validation area under the curve (AUC) = 0.94), showing that semaglutide treatment results in a specific serum proteomic signature.</data>
      <data key="d3">The STEP 1 signature had a high classification performance (internal nested cross-validation area under the curve (AUC) = 0.94), showing that semaglutide treatment results in a specific serum proteomic signature.</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Result_-8827963784690564189">
      <data key="d0">Result</data>
      <data key="d1">Using data from STEP 1 and STEP 2, we found that semaglutide treatment reduced this CVD risk score compared with placebo</data>
      <data key="d3">Using data from STEP 1 and STEP 2, we found that semaglutide treatment reduced this CVD risk score compared with placebo</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Conclusion_-6230425390282510934">
      <data key="d0">Conclusion</data>
      <data key="d1">the lack of a dose response on CVD risk with semaglutide 1.0 mg and 2.4 mg in STEP 2 supports semaglutide effects on CVD beyond weight loss.</data>
      <data key="d3">the lack of a dose response on CVD risk with semaglutide 1.0 mg and 2.4 mg in STEP 2 supports semaglutide effects on CVD beyond weight loss.</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_7_Hypothesis_-6851688615719123305">
      <data key="d0">Hypothesis</data>
      <data key="d1">This hypothesis will be tested using proteomic data from the SELECT trial36 for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
      <data key="d3">This hypothesis will be tested using proteomic data from the SELECT trial36 for the six cardiovascular proteins listed above that were downregulated by semaglutide in STEP 1.</data>
      <data key="d4">PDF_7</data>
    </node>
    <node id="PDF_14">
      <data key="d0">Paper</data>
      <data key="d1">Here is the full text from the provided scientific PDF, with the OCR-generated text presented as accurately as possible (including any OCR errors or formatting issues)

JAFRICA CARDIOVASCULAR JOURNAL OF AFRICA • Vol 20, No 2, March/April 2009
127
Review Article
Perindopril: do randomised, controlled trials support an
ACE inhibitor class effect? A meta-analysis of clinical
trials
JACQUES R SNYMAN, FRANCOIS WESSELS
Summary
Background: Due to the lack of face-to-face trials between
ACE inhibitors, </data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_14_Result_-8915218293332595416">
      <data key="d0">Result</data>
      <data key="d1">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
      <data key="d3">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="Disease_MYOCARDIAL INFARCTION">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">MYOCARDIAL INFARCTION</data>
      <data key="d7">Myocardial Infarction</data>
    </node>
    <node id="Disease_STROKE">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">STROKE</data>
      <data key="d7">stroke</data>
    </node>
    <node id="Process_MORTALITY">
      <data key="d0">Entity</data>
      <data key="d5">Process</data>
      <data key="d6">MORTALITY</data>
      <data key="d7">mortality</data>
    </node>
    <node id="PDF_14_Conclusion_5692981340058967712">
      <data key="d0">Conclusion</data>
      <data key="d1">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
      <data key="d3">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_-7269795294449655842">
      <data key="d0">Result</data>
      <data key="d1">The effect size for perindopril alone was larger than that of the combined ACEI analysis.</data>
      <data key="d3">The effect size for perindopril alone was larger than that of the combined ACEI analysis.</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_-7758215992716246093">
      <data key="d0">Result</data>
      <data key="d1">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
      <data key="d3">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_7546556218369098929">
      <data key="d0">Result</data>
      <data key="d1">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039)</data>
      <data key="d3">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039)</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_-4843215839429067794">
      <data key="d0">Result</data>
      <data key="d1">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
      <data key="d3">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_5581553987613849359">
      <data key="d0">Result</data>
      <data key="d1">The effect of perindopril on stroke demonstrated a highly significant reduction in event rate (OR 0.79; 95% CI: 0.72-0.86; p &lt; 0.0001). However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287)</data>
      <data key="d3">The effect of perindopril on stroke demonstrated a highly significant reduction in event rate (OR 0.79; 95% CI: 0.72-0.86; p &lt; 0.0001). However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287)</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_1626576483297861981">
      <data key="d0">Result</data>
      <data key="d1">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008)</data>
      <data key="d3">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008)</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_14_Result_69690161036949378">
      <data key="d0">Result</data>
      <data key="d1">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92-0.98; p = 0.0033).</data>
      <data key="d3">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92-0.98; p = 0.0033).</data>
      <data key="d4">PDF_14</data>
    </node>
    <node id="PDF_3">
      <data key="d0">Paper</data>
      <data key="d1">LTH &amp; HUMAN SERVICES-US,
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
HHS Public Access
Author manuscript
Nat Metab. Author manuscript; available in PMC 2021 August 15.
Published in final edited form as:
Nat Metab. 2021 February ; 3(2): 258–273. doi:10.1038/s42255-021-00344-4.
Central and peripheral GLP-1 systems independently suppress
eating
Daniel I. Brierley¹, Marie K. Holt2, Arashdeep Singh3,7, Alan de Araujo 3,7, Molly
McDougle 3,7, Macarena Vergara3,7, Majd H. Af</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_3_Hypothesis_6221589398331814564">
      <data key="d0">Hypothesis</data>
      <data key="d1">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
      <data key="d3">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="Gene_PPG">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">PPG</data>
      <data key="d7">PPG</data>
    </node>
    <node id="PDF_3_Method_-2129798450090827598">
      <data key="d0">Method</data>
      <data key="d1">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
      <data key="d3">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="Gene_PPGNTS">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">PPGNTS</data>
      <data key="d7">PPGNTS</data>
    </node>
    <node id="Protein_DTA">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">DTA</data>
      <data key="d7">DTA</data>
    </node>
    <node id="PDF_3_Method_5057154544204677720">
      <data key="d0">Method</data>
      <data key="d1">chemogenetic inhibition of PPGNTS neurons on termination of large solid and liquid meals, using the inhibitory hM4Di Designer Receptor Exclusively Activated by Designer Drugs (DREADD)</data>
      <data key="d3">chemogenetic inhibition of PPGNTS neurons on termination of large solid and liquid meals, using the inhibitory hM4Di Designer Receptor Exclusively Activated by Designer Drugs (DREADD)</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Method_771869393751147769">
      <data key="d0">Method</data>
      <data key="d1">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice</data>
      <data key="d3">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="Gene_GLP-1R">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">GLP-1R</data>
      <data key="d7">GLP-1R</data>
    </node>
    <node id="PDF_3_Method_599907980140553093">
      <data key="d0">Method</data>
      <data key="d1">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
      <data key="d3">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="Gene_OXTR">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">OXTR</data>
      <data key="d7">Oxtr</data>
    </node>
    <node id="PDF_3_Result_-299893572724238923">
      <data key="d0">Result</data>
      <data key="d1">chemogenetic activation of PPGNTS neurons activated 82% of transduced neurons</data>
      <data key="d3">chemogenetic activation of PPGNTS neurons activated 82% of transduced neurons</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Result_8850959385062359021">
      <data key="d0">Result</data>
      <data key="d1">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
      <data key="d3">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Result_923860893507256371">
      <data key="d0">Result</data>
      <data key="d1">Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
      <data key="d3">Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Result_2820051245537628533">
      <data key="d0">Result</data>
      <data key="d1">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
      <data key="d3">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Result_1621174394233847305">
      <data key="d0">Result</data>
      <data key="d1">Superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
      <data key="d3">Superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="Protein_OXYTOCIN">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">OXYTOCIN</data>
      <data key="d7">oxytocin</data>
    </node>
    <node id="PDF_3_Result_2502046257461297142">
      <data key="d0">Result</data>
      <data key="d1">While oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
      <data key="d3">While oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Result_5985350942412134511">
      <data key="d0">Result</data>
      <data key="d1">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
      <data key="d3">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Conclusion_1929525825689517844">
      <data key="d0">Conclusion</data>
      <data key="d1">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits</data>
      <data key="d3">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Conclusion_8337216335006696470">
      <data key="d0">Conclusion</data>
      <data key="d1">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
      <data key="d3">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_3_Conclusion_3130345879434505383">
      <data key="d0">Conclusion</data>
      <data key="d1">PPGNTS neurons are not recruited by peripherally administered semaglutide, or required for the anorexigenic effects of liraglutide or semaglutide, and concurrent activation of PPGNTS neurons augments semaglutide-induced eating suppression</data>
      <data key="d3">PPGNTS neurons are not recruited by peripherally administered semaglutide, or required for the anorexigenic effects of liraglutide or semaglutide, and concurrent activation of PPGNTS neurons augments semaglutide-induced eating suppression</data>
      <data key="d4">PDF_3</data>
    </node>
    <node id="PDF_4">
      <data key="d0">Paper</data>
      <data key="d1">nature medicine
Article
a
https://doi.org/10.1038/s41591-024-02996-7
Long-term weight loss effects of semaglutide
in obesity without diabetes in the SELECT trial
Received: 1 March 2024
Accepted: 12 April 2024
Published online: 13 May 2024
Check for updates
Donna H. Ryan', Ildiko Lingvay 2, John Deanfield³, Steven E. Kahn,
Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato 8,
Dror Dicker, Deborah B. Horn¹º, G. Kees Hovingh, Ole Kleist Jeppesen,
Alexander Kokkinos", A. Michael Linco</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_4_Result_-7309760128306513036">
      <data key="d0">Result</data>
      <data key="d1">In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.</data>
      <data key="d3">In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_1472442981486919918">
      <data key="d0">Result</data>
      <data key="d1">At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P &lt; 0.0001 for all comparisons versus placebo).</data>
      <data key="d3">At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P &lt; 0.0001 for all comparisons versus placebo).</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_-3085720973791383362">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide was associated with fewer serious adverse events.</data>
      <data key="d3">Semaglutide was associated with fewer serious adverse events.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_2254116346577049562">
      <data key="d0">Result</data>
      <data key="d1">At week 208, mean weight loss in the semaglutide group analyzed as first on-treatment was -11.7% compared with -1.5% for the placebo group.</data>
      <data key="d3">At week 208, mean weight loss in the semaglutide group analyzed as first on-treatment was -11.7% compared with -1.5% for the placebo group.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_-1177706342943020559">
      <data key="d0">Result</data>
      <data key="d1">Among in-trial (intention-to-treat principle) patients at week 104, weight loss of≥5%, ≥10%, ≥15%, ≥20% and ≥25% was achieved by 67.8%, 44.2%, 22.9%, 11.0% and 4.9%, respectively, of those treated with semaglutide compared with 21.3%, 6.9%, 1.7%, 0.6% and 0.1% of those receiving placebo.</data>
      <data key="d3">Among in-trial (intention-to-treat principle) patients at week 104, weight loss of≥5%, ≥10%, ≥15%, ≥20% and ≥25% was achieved by 67.8%, 44.2%, 22.9%, 11.0% and 4.9%, respectively, of those treated with semaglutide compared with 21.3%, 6.9%, 1.7%, 0.6% and 0.1% of those receiving placebo.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_-4682530704327295254">
      <data key="d0">Result</data>
      <data key="d1">At week 208, average reduction in WC was -7.7 cm with semaglutide versus -1.3 cm with placebo, with a treatment difference of -6.4 cm (95% CI-7.18 to-5.61; P&lt;0.0001)21.</data>
      <data key="d3">At week 208, average reduction in WC was -7.7 cm with semaglutide versus -1.3 cm with placebo, with a treatment difference of -6.4 cm (95% CI-7.18 to-5.61; P&lt;0.0001)21.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_684292181619973767">
      <data key="d0">Result</data>
      <data key="d1">At week 208, in the group randomized to semaglutide, there was a relative reduction of 6.9% in WHtR compared with 1.0% in placebo (treatment difference -5.87% points; 95% CI-6.56 to-5.17; P&lt;0.0001).</data>
      <data key="d3">At week 208, in the group randomized to semaglutide, there was a relative reduction of 6.9% in WHtR compared with 1.0% in placebo (treatment difference -5.87% points; 95% CI-6.56 to-5.17; P&lt;0.0001).</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_-3398238003419588495">
      <data key="d0">Result</data>
      <data key="d1">At week 104, 52.4% of patients treated with semaglutide achieved improvement in BMI category compared with 15.7% of those receiving placebo.</data>
      <data key="d3">At week 104, 52.4% of patients treated with semaglutide achieved improvement in BMI category compared with 15.7% of those receiving placebo.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_2629134144249230609">
      <data key="d0">Result</data>
      <data key="d1">In the semaglutide group, 12.0% of patients achieved a BMI&lt;25 kg m¯², which is considered the healthy BMI category, compared with 1.2% for placebo; per study inclusion criteria, no patients were in this category at baseline.</data>
      <data key="d3">In the semaglutide group, 12.0% of patients achieved a BMI&lt;25 kg m¯², which is considered the healthy BMI category, compared with 1.2% for placebo; per study inclusion criteria, no patients were in this category at baseline.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_3585129967545597750">
      <data key="d0">Result</data>
      <data key="d1">Women had a greater difference in mean weight loss with semaglutide versus placebo (-11.1% (95% CI -11.56 to -10.66) versus -7.5% in men (95% CI -7.78 to -7.23); P &lt; 0.0001).</data>
      <data key="d3">Women had a greater difference in mean weight loss with semaglutide versus placebo (-11.1% (95% CI -11.56 to -10.66) versus -7.5% in men (95% CI -7.78 to -7.23); P &lt; 0.0001).</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_-7560771698952097683">
      <data key="d0">Result</data>
      <data key="d1">For lower BMI classes, discontinuation rates are higher in the semaglutide group but not the placebo group.</data>
      <data key="d3">For lower BMI classes, discontinuation rates are higher in the semaglutide group but not the placebo group.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_4_Result_-6836731396123171278">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide was associated with lower SAEs, primarily driven by CV event and infections.</data>
      <data key="d3">Semaglutide was associated with lower SAEs, primarily driven by CV event and infections.</data>
      <data key="d4">PDF_4</data>
    </node>
    <node id="PDF_5">
      <data key="d0">Paper</data>
      <data key="d1">www.nature.com/scientificreports

scientific reports
OPEN A GLP1 receptor agonist
Check for updates
diabetes drug ameliorates
neurodegeneration in a mouse
model of infantile neurometabolic
disease
L. Poupon-Bejuit1,2, M. P. Hughes1,2, W. Liu¹, A. Geard¹, N. Faour-Slika¹, S. Whaler¹,
G. Massaro1 &amp; A. A. Rahim1
Infantile neuroaxonal dystrophy (INAD) is a rare paediatric neurodegenerative condition caused by
mutations in the PLA2G6 gene, which is also the causative gene for PARK14-linked young adul</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_5_Hypothesis_-8856319259921474255">
      <data key="d0">Hypothesis</data>
      <data key="d1">We investigated the therapeutic efficacy of the GLP-1R agonist semaglutide in a mouse model of INAD.</data>
      <data key="d3">We investigated the therapeutic efficacy of the GLP-1R agonist semaglutide in a mouse model of INAD.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="Disease_INAD">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">INAD</data>
      <data key="d7">INAD</data>
    </node>
    <node id="PDF_5_Method_-2436680410126177391">
      <data key="d0">Method</data>
      <data key="d1">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
      <data key="d3">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="Gene_PLA2G6">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">PLA2G6</data>
      <data key="d7">Pla2g6</data>
    </node>
    <node id="PDF_5_Result_2710636421122754870">
      <data key="d0">Result</data>
      <data key="d1">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice.</data>
      <data key="d3">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_-4141003330907677127">
      <data key="d0">Result</data>
      <data key="d1">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
      <data key="d3">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_-1002101900670632989">
      <data key="d0">Result</data>
      <data key="d1">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
      <data key="d3">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_-4412264048747100113">
      <data key="d0">Result</data>
      <data key="d1">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
      <data key="d3">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_-7938757989094910463">
      <data key="d0">Result</data>
      <data key="d1">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-¹- mice.</data>
      <data key="d3">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-¹- mice.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="Protein_CD68">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">CD68</data>
      <data key="d7">CD68</data>
    </node>
    <node id="PDF_5_Result_8878235989260343804">
      <data key="d0">Result</data>
      <data key="d1">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-¹- controls.</data>
      <data key="d3">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-¹- controls.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_4864384080983545575">
      <data key="d0">Result</data>
      <data key="d1">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-¹- mice in the cortex</data>
      <data key="d3">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-¹- mice in the cortex</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_4028748785160573470">
      <data key="d0">Result</data>
      <data key="d1">Treatment with semaglutide resulted in up-regulation of GLP-1R expression suggesting a feed-back loop upon activation of the receptor.</data>
      <data key="d3">Treatment with semaglutide resulted in up-regulation of GLP-1R expression suggesting a feed-back loop upon activation of the receptor.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_860370958687953436">
      <data key="d0">Result</data>
      <data key="d1">The level of CREB mRNA was reduced in untreated Pla2g6¯¹- mice and normalised in the high-dose semaglutide-treated group.</data>
      <data key="d3">The level of CREB mRNA was reduced in untreated Pla2g6¯¹- mice and normalised in the high-dose semaglutide-treated group.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="Protein_CREB">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">CREB</data>
      <data key="d7">CREB</data>
    </node>
    <node id="PDF_5_Result_-8661222603736243328">
      <data key="d0">Result</data>
      <data key="d1">Our study demonstrates the presence of apoptosis through modulation of BCl-2 family members, which was largely reversed by semaglutide treatment.</data>
      <data key="d3">Our study demonstrates the presence of apoptosis through modulation of BCl-2 family members, which was largely reversed by semaglutide treatment.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="Protein_BCL-2">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">BCL-2</data>
      <data key="d7">BCl-2</data>
    </node>
    <node id="Process_APOPTOSIS">
      <data key="d0">Entity</data>
      <data key="d5">Process</data>
      <data key="d6">APOPTOSIS</data>
      <data key="d7">apoptosis</data>
    </node>
    <node id="PDF_5_Result_426357961769712333">
      <data key="d0">Result</data>
      <data key="d1">This upregulation was reduced following treatment with the GLP-1R agonist.</data>
      <data key="d3">This upregulation was reduced following treatment with the GLP-1R agonist.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Result_7791270865785449861">
      <data key="d0">Result</data>
      <data key="d1">Treatment with the GLP-1R agonist affects the transcriptional regulation of GSK3ẞ resulting in significant reduction and normalisation to wild-type levels.</data>
      <data key="d3">Treatment with the GLP-1R agonist affects the transcriptional regulation of GSK3ẞ resulting in significant reduction and normalisation to wild-type levels.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="Protein_GSK3ẞ">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">GSK3ẞ</data>
      <data key="d7">GSK3ẞ</data>
    </node>
    <node id="PDF_5_Conclusion_-1586288735173776015">
      <data key="d0">Conclusion</data>
      <data key="d1">Here, we demonstrate that 0.5 µg/g semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
      <data key="d3">Here, we demonstrate that 0.5 µg/g semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_5_Conclusion_8037783431905148000">
      <data key="d0">Conclusion</data>
      <data key="d1">Semaglutide represents a new potential therapeutic agent that could decelerate disease progression and potentially improve the patient's quality of life.</data>
      <data key="d3">Semaglutide represents a new potential therapeutic agent that could decelerate disease progression and potentially improve the patient's quality of life.</data>
      <data key="d4">PDF_5</data>
    </node>
    <node id="PDF_12">
      <data key="d0">Paper</data>
      <data key="d1">Drugs 1996; 52 Suppl. 3: 39-47
0012-6667/96/0003-0039/$04.50/0
Adis International Limited. All rights reserved.
Pharmacology and Clinical Experience
with Tramadol in Osteoarthritis
Warren A. Katz
University of Pennsylvania Health System, Presbyterian Medical Center, Philadelphia,
Pennsylvania, USA
Summary
Tramadol is a centrally acting analgesic that has been shown to be effective
in a variety of acute and chronic pain states. Unlike other centrally acting anal-
gesics, it exerts a dual action b</data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_12_Result_-6774985175915621860">
      <data key="d0">Result</data>
      <data key="d1">Tramadol is a centrally acting analgesic that has been shown to be effective in a variety of acute and chronic pain states.</data>
      <data key="d3">Tramadol is a centrally acting analgesic that has been shown to be effective in a variety of acute and chronic pain states.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_TRAMADOL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">TRAMADOL</data>
      <data key="d7">Tramadol</data>
    </node>
    <node id="PDF_12_Result_-2999995781462909448">
      <data key="d0">Result</data>
      <data key="d1">Tramadol exerts a dual action by binding to the opioid receptor site in the central nervous system and by weakly inhibiting the reuptake of biogenic amines.</data>
      <data key="d3">Tramadol exerts a dual action by binding to the opioid receptor site in the central nervous system and by weakly inhibiting the reuptake of biogenic amines.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-4502596496072044522">
      <data key="d0">Result</data>
      <data key="d1">Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration.</data>
      <data key="d3">Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_8026474705881486032">
      <data key="d0">Result</data>
      <data key="d1">Tramadol would appear to be particularly useful in the elderly population affected by osteoarthritis because, unlike nonsteroidal anti-inflammatory drugs, it does not aggravate hypertension or congestive heart failure, nor does it have the potential to cause peptic ulcer disease.</data>
      <data key="d3">Tramadol would appear to be particularly useful in the elderly population affected by osteoarthritis because, unlike nonsteroidal anti-inflammatory drugs, it does not aggravate hypertension or congestive heart failure, nor does it have the potential to cause peptic ulcer disease.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Disease_OSTEOARTHRITIS">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">OSTEOARTHRITIS</data>
      <data key="d7">Osteoarthritis</data>
    </node>
    <node id="PDF_12_Result_2359535798452715126">
      <data key="d0">Result</data>
      <data key="d1">Compared with narcotics, tramadol does not induce significant respiratory depression, constipation, or have significant abuse potential.</data>
      <data key="d3">Compared with narcotics, tramadol does not induce significant respiratory depression, constipation, or have significant abuse potential.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_2916758855844091943">
      <data key="d0">Result</data>
      <data key="d1">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
      <data key="d3">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_420969686020344714">
      <data key="d0">Result</data>
      <data key="d1">tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action</data>
      <data key="d3">tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_NALOXONE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">NALOXONE</data>
      <data key="d7">naloxone</data>
    </node>
    <node id="PDF_12_Result_-7897340407270493618">
      <data key="d0">Result</data>
      <data key="d1">Tramadol has definite selectivity for the u opioid receptor compared with the 8 and к opioid receptors.</data>
      <data key="d3">Tramadol has definite selectivity for the u opioid receptor compared with the 8 and к opioid receptors.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_7630098172249293658">
      <data key="d0">Result</data>
      <data key="d1">The pharmacokinetic profile of oral tramadol reflects its 75% bioavailability (rising to 100% with multiple administration), which is not significantly altered when the drug is administered with food.</data>
      <data key="d3">The pharmacokinetic profile of oral tramadol reflects its 75% bioavailability (rising to 100% with multiple administration), which is not significantly altered when the drug is administered with food.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-4869032256513921850">
      <data key="d0">Result</data>
      <data key="d1">Respiratory depression is uncommon with tramadol administration and has occurred only when the recommended dose has been considerably exceeded (overdose) or in conjunction with drugs that themselves depress respiration.</data>
      <data key="d3">Respiratory depression is uncommon with tramadol administration and has occurred only when the recommended dose has been considerably exceeded (overdose) or in conjunction with drugs that themselves depress respiration.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_1263465287594110931">
      <data key="d0">Result</data>
      <data key="d1">Regular administration seems to be more efficacious for the management of painful osteoarthritis</data>
      <data key="d3">Regular administration seems to be more efficacious for the management of painful osteoarthritis</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-6268527559379590944">
      <data key="d0">Result</data>
      <data key="d1">The effect of tramadol on the plasma concentration of monoamine oxidase (MAO) inhibitors has not been studied.</data>
      <data key="d3">The effect of tramadol on the plasma concentration of monoamine oxidase (MAO) inhibitors has not been studied.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-5981291692107001170">
      <data key="d0">Result</data>
      <data key="d1">Clinically, coadministration of tramadol with NSAIDs has produced additive analgesic effects, and in animal models clear synergy has been found between tramadol and a number of NSAIDs</data>
      <data key="d3">Clinically, coadministration of tramadol with NSAIDs has produced additive analgesic effects, and in animal models clear synergy has been found between tramadol and a number of NSAIDs</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_6793792303088618948">
      <data key="d0">Result</data>
      <data key="d1">Tramadol at the usual doses has rarely been associated with respiratory depression</data>
      <data key="d3">Tramadol at the usual doses has rarely been associated with respiratory depression</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_4000149532510856180">
      <data key="d0">Result</data>
      <data key="d1">tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg</data>
      <data key="d3">tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_CODEINE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">CODEINE</data>
      <data key="d7">codeine</data>
    </node>
    <node id="PDF_12_Result_625662708329867935">
      <data key="d0">Result</data>
      <data key="d1">tramadol provided analgesia comparable to that of the reference agents, although there were no statistically significant differences between the treatment groups</data>
      <data key="d3">tramadol provided analgesia comparable to that of the reference agents, although there were no statistically significant differences between the treatment groups</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-7422617096255101567">
      <data key="d0">Result</data>
      <data key="d1">Significantly more tramadol-treated patients completed the study. An average daily dosage of 245mg was significantly more effective than placebo in reducing the severity of the pain at rest.</data>
      <data key="d3">Significantly more tramadol-treated patients completed the study. An average daily dosage of 245mg was significantly more effective than placebo in reducing the severity of the pain at rest.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_8073815806234392537">
      <data key="d0">Result</data>
      <data key="d1">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine.</data>
      <data key="d3">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_PENTAZOCINE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">PENTAZOCINE</data>
      <data key="d7">pentazocine</data>
    </node>
    <node id="PDF_12_Result_3951732065118766371">
      <data key="d0">Result</data>
      <data key="d1">Tramadol was more effective in terms of morning stiffness and the need for concomitant paracetamol.</data>
      <data key="d3">Tramadol was more effective in terms of morning stiffness and the need for concomitant paracetamol.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_PARACETAMOL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">PARACETAMOL</data>
      <data key="d7">Paracetamol</data>
    </node>
    <node id="PDF_12_Result_3258887076067917652">
      <data key="d0">Result</data>
      <data key="d1">tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
      <data key="d3">tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_DEXTROPROPOXYPHENE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">DEXTROPROPOXYPHENE</data>
      <data key="d7">dextropropoxyphene</data>
    </node>
    <node id="PDF_12_Result_449362107409668405">
      <data key="d0">Result</data>
      <data key="d1">both drugs showed comparable efficacy after 4 weeks. The mean daily dose of tramadol was 164.8mg and that of diclofenac was 86.9mg.</data>
      <data key="d3">both drugs showed comparable efficacy after 4 weeks. The mean daily dose of tramadol was 164.8mg and that of diclofenac was 86.9mg.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_DICLOFENAC">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">DICLOFENAC</data>
      <data key="d7">diclofenac</data>
    </node>
    <node id="PDF_12_Result_8502938962552273800">
      <data key="d0">Result</data>
      <data key="d1">a mean daily tramadol dose of 160mg (maximum total dose of 400mg) for up to 4 weeks produced overall ‘satisfactory' pain relief in approximately 86% of patients</data>
      <data key="d3">a mean daily tramadol dose of 160mg (maximum total dose of 400mg) for up to 4 weeks produced overall ‘satisfactory' pain relief in approximately 86% of patients</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-7336713307888196122">
      <data key="d0">Result</data>
      <data key="d1">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis, apparently because the degree of inflammation is not great.</data>
      <data key="d3">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis, apparently because the degree of inflammation is not great.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_7754024338876440667">
      <data key="d0">Result</data>
      <data key="d1">Both drugs demonstrated equivalent efficacy.</data>
      <data key="d3">Both drugs demonstrated equivalent efficacy.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-2116604159937777599">
      <data key="d0">Result</data>
      <data key="d1">the incidence of dizziness (6.8%), nausea (10.3%), constipation (6.8%) or somnolence (6.0%) was not appreciably different from that with paracetamol plus codeine or aspirin plus codeine</data>
      <data key="d3">the incidence of dizziness (6.8%), nausea (10.3%), constipation (6.8%) or somnolence (6.0%) was not appreciably different from that with paracetamol plus codeine or aspirin plus codeine</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_ASPIRIN">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">ASPIRIN</data>
      <data key="d7">aspirin</data>
    </node>
    <node id="PDF_12_Result_-1856213236509705757">
      <data key="d0">Result</data>
      <data key="d1">Tramadol produces effects similar to those of an opioid, yet the development of tolerance has been reported to be relatively mild, and symptoms of withdrawal, when present, are not considered to be as severe as those produced by other opioids.</data>
      <data key="d3">Tramadol produces effects similar to those of an opioid, yet the development of tolerance has been reported to be relatively mild, and symptoms of withdrawal, when present, are not considered to be as severe as those produced by other opioids.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Result_-1676962246853325250">
      <data key="d0">Result</data>
      <data key="d1">tolerance to the analgesic effect of tramadol after repeated administration was minimal and less than that produced by morphine</data>
      <data key="d3">tolerance to the analgesic effect of tramadol after repeated administration was minimal and less than that produced by morphine</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_MORPHINE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">MORPHINE</data>
      <data key="d7">morphine</data>
    </node>
    <node id="PDF_12_Result_1247314472091141845">
      <data key="d0">Result</data>
      <data key="d1">Paracetamol is a reasonable first-line approach because of the excellent benefit/risk/cost ratio. If low dose intermittent ibuprofen, in over-the-counter dosages, can be used with good pain relief, then there is no good reason to use tramadol. However, if ibuprofen is not sufficiently efficacious, or produces adverse effects, or if the patient has a relative or absolute contraindication, then tramadol can be used, especially if the patient has failed to respond to paracetamol.</data>
      <data key="d3">Paracetamol is a reasonable first-line approach because of the excellent benefit/risk/cost ratio. If low dose intermittent ibuprofen, in over-the-counter dosages, can be used with good pain relief, then there is no good reason to use tramadol. However, if ibuprofen is not sufficiently efficacious, or produces adverse effects, or if the patient has a relative or absolute contraindication, then tramadol can be used, especially if the patient has failed to respond to paracetamol.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="Compound_IBUPROFEN">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">IBUPROFEN</data>
      <data key="d7">Ibuprofen</data>
    </node>
    <node id="PDF_12_Method_2731279007154695014">
      <data key="d0">Method</data>
      <data key="d1">tramadol is a single-entity, centrally acting analgesic</data>
      <data key="d3">tramadol is a single-entity, centrally acting analgesic</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Method_775100123491143823">
      <data key="d0">Method</data>
      <data key="d1">tramadol binds to the u opioid receptor site in the central nervous system</data>
      <data key="d3">tramadol binds to the u opioid receptor site in the central nervous system</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Method_-6133997904598456722">
      <data key="d0">Method</data>
      <data key="d1">tramadol inhibits the uptake of noradrenaline and serotonin</data>
      <data key="d3">tramadol inhibits the uptake of noradrenaline and serotonin</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_12_Conclusion_596753725548238670">
      <data key="d0">Conclusion</data>
      <data key="d1">The availability of tramadol as an analgesic for the management of painful osteoarthritis represents a desirable therapeutic option.</data>
      <data key="d3">The availability of tramadol as an analgesic for the management of painful osteoarthritis represents a desirable therapeutic option.</data>
      <data key="d4">PDF_12</data>
    </node>
    <node id="PDF_11">
      <data key="d0">Paper</data>
      <data key="d1">DRUG EVALUATION
Drugs 42 (1): 90-114, 1991
0012-6667/91/0007-0090/$12.50/0
Adis International Limited. All rights reserved.
DRE1 15
Perindopril
A Review of its Pharmacological Properties and Therapeutic Use in
Cardiovascular Disorders
Peter A. Todd and Andrew Fitton
Adis International Limited, Auckland, New Zealand
Various sections of the manuscript reviewed by: A. Breckenridge, Department of Pharmacology and Therapeutics,
University of Liverpool, Liverpool, England; K. Dickstein, Department of </data>
      <data key="d2">2024</data>
    </node>
    <node id="PDF_11_Result_4197650708690233955">
      <data key="d0">Result</data>
      <data key="d1">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
      <data key="d3">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Disease_HYPERTENSION">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">HYPERTENSION</data>
      <data key="d7">Hypertension</data>
    </node>
    <node id="PDF_11_Result_354537486303178723">
      <data key="d0">Result</data>
      <data key="d1">Those patients who do not respond adequately to monotherapy with perindopril usually respond with the addition of a second agent, such as a thiazide diuretic.</data>
      <data key="d3">Those patients who do not respond adequately to monotherapy with perindopril usually respond with the addition of a second agent, such as a thiazide diuretic.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_4184705004567467970">
      <data key="d0">Result</data>
      <data key="d1">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
      <data key="d3">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Compound_CAPTOPRIL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">CAPTOPRIL</data>
      <data key="d7">Captopril</data>
    </node>
    <node id="Compound_ATENOLOL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">ATENOLOL</data>
      <data key="d7">Atenolol</data>
    </node>
    <node id="Compound_HYDROCHLOROTHIAZIDE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">HYDROCHLOROTHIAZIDE</data>
      <data key="d7">Hydrochlorothiazide</data>
    </node>
    <node id="PDF_11_Result_-6784970168649026019">
      <data key="d0">Result</data>
      <data key="d1">Perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
      <data key="d3">Perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Disease_HEART FAILURE">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">HEART FAILURE</data>
      <data key="d7">Heart Failure</data>
    </node>
    <node id="PDF_11_Result_-260179632625917423">
      <data key="d0">Result</data>
      <data key="d1">Perindopril is likely to represent a useful alternative to other members of the ACE inhibitor class in all grades of hypertension and congestive heart failure.</data>
      <data key="d3">Perindopril is likely to represent a useful alternative to other members of the ACE inhibitor class in all grades of hypertension and congestive heart failure.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_4774744813425608663">
      <data key="d0">Result</data>
      <data key="d1">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
      <data key="d3">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Gene_ACE">
      <data key="d0">Entity</data>
      <data key="d5">Gene</data>
      <data key="d6">ACE</data>
      <data key="d7">ACE</data>
    </node>
    <node id="Protein_ANGIOTENSIN II">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">ANGIOTENSIN II</data>
      <data key="d7">Angiotensin II</data>
    </node>
    <node id="PDF_11_Result_4733928251773593198">
      <data key="d0">Result</data>
      <data key="d1">Inhibition of angiotensin II formation, in particular in the vasculature, is the primary pharmacological action of perindopril, leading to a reduction in peripheral vascular resistance with no significant change in heart rate.</data>
      <data key="d3">Inhibition of angiotensin II formation, in particular in the vasculature, is the primary pharmacological action of perindopril, leading to a reduction in peripheral vascular resistance with no significant change in heart rate.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_4631797196767407880">
      <data key="d0">Result</data>
      <data key="d1">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
      <data key="d3">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-754730249218087050">
      <data key="d0">Result</data>
      <data key="d1">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
      <data key="d3">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-7987352542641189223">
      <data key="d0">Result</data>
      <data key="d1">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
      <data key="d3">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_3767974454484220477">
      <data key="d0">Result</data>
      <data key="d1">Perindopril is rapidly absorbed, reaching peak plasma concentrations about 1 hour after a single oral dose, and is cleared from the circulation in about 6 hours.</data>
      <data key="d3">Perindopril is rapidly absorbed, reaching peak plasma concentrations about 1 hour after a single oral dose, and is cleared from the circulation in about 6 hours.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-5841757439011772607">
      <data key="d0">Result</data>
      <data key="d1">Only about 17 to 20% of the orally administered dose is available as perindoprilat, as extensive metabolism to other inactive metabolites occurs.</data>
      <data key="d3">Only about 17 to 20% of the orally administered dose is available as perindoprilat, as extensive metabolism to other inactive metabolites occurs.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Compound_PERINDOPRILAT">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">PERINDOPRILAT</data>
      <data key="d7">Perindoprilat</data>
    </node>
    <node id="PDF_11_Result_1200982518153901137">
      <data key="d0">Result</data>
      <data key="d1">The use of perindopril in potentially at-risk hypertensive patients, such as the elderly and those with diabetes or renal impairment, has not been associated with any unfavourable metabolic changes.</data>
      <data key="d3">The use of perindopril in potentially at-risk hypertensive patients, such as the elderly and those with diabetes or renal impairment, has not been associated with any unfavourable metabolic changes.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Disease_DIABETES">
      <data key="d0">Entity</data>
      <data key="d5">Disease</data>
      <data key="d6">DIABETES</data>
      <data key="d7">Diabetes</data>
    </node>
    <node id="PDF_11_Result_-731215718995173322">
      <data key="d0">Result</data>
      <data key="d1">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
      <data key="d3">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_5198197461515115468">
      <data key="d0">Result</data>
      <data key="d1">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
      <data key="d3">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-6976160984899220301">
      <data key="d0">Result</data>
      <data key="d1">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
      <data key="d3">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-7431969788317810718">
      <data key="d0">Result</data>
      <data key="d1">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
      <data key="d3">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_7019794477971046434">
      <data key="d0">Result</data>
      <data key="d1">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
      <data key="d3">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-8011367986389430369">
      <data key="d0">Result</data>
      <data key="d1">Perindopril, a new member of this drug class, is chemically related to enalapril</data>
      <data key="d3">Perindopril, a new member of this drug class, is chemically related to enalapril</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Compound_ENALAPRIL">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">ENALAPRIL</data>
      <data key="d7">Enalapril</data>
    </node>
    <node id="PDF_11_Result_3350740205061296852">
      <data key="d0">Result</data>
      <data key="d1">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
      <data key="d3">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Compound_ENALAPRILAT">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">ENALAPRILAT</data>
      <data key="d7">Enalaprilat</data>
    </node>
    <node id="PDF_11_Result_-8402194948833182832">
      <data key="d0">Result</data>
      <data key="d1">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
      <data key="d3">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-2181958032508705436">
      <data key="d0">Result</data>
      <data key="d1">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
      <data key="d3">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_314771194671321701">
      <data key="d0">Result</data>
      <data key="d1">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
      <data key="d3">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Protein_ANGIOTENSIN I">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">ANGIOTENSIN I</data>
      <data key="d7">Angiotensin I</data>
    </node>
    <node id="PDF_11_Result_5662459425840310734">
      <data key="d0">Result</data>
      <data key="d1">Human studies have indicated that the maximal ACE inhibitory response to orally ad- ministered perindopril is attained with a single 8 to 16mg dose; ACE inhibition occurs with an onset 1 hour after administration, reaches a maximum at about 4 to 8 hours, and is maintained for 24 hours.</data>
      <data key="d3">Human studies have indicated that the maximal ACE inhibitory response to orally ad- ministered perindopril is attained with a single 8 to 16mg dose; ACE inhibition occurs with an onset 1 hour after administration, reaches a maximum at about 4 to 8 hours, and is maintained for 24 hours.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-2258662557350811308">
      <data key="d0">Result</data>
      <data key="d1">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
      <data key="d3">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_8781159825379823151">
      <data key="d0">Result</data>
      <data key="d1">administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
      <data key="d3">administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_7306967139259324869">
      <data key="d0">Result</data>
      <data key="d1">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
      <data key="d3">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Protein_BRADYKININ">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">BRADYKININ</data>
      <data key="d7">Bradykinin</data>
    </node>
    <node id="Compound_PROSTAGLANDINS">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">PROSTAGLANDINS</data>
      <data key="d7">Prostaglandins</data>
    </node>
    <node id="PDF_11_Result_-2315276413657724531">
      <data key="d0">Result</data>
      <data key="d1">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
      <data key="d3">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Protein_RENIN">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">RENIN</data>
      <data key="d7">Renin</data>
    </node>
    <node id="PDF_11_Result_-7034928497063358712">
      <data key="d0">Result</data>
      <data key="d1">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
      <data key="d3">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Protein_ATRIAL NATRIURETIC FACTOR">
      <data key="d0">Entity</data>
      <data key="d5">Protein</data>
      <data key="d6">ATRIAL NATRIURETIC FACTOR</data>
      <data key="d7">Atrial natriuretic factor</data>
    </node>
    <node id="PDF_11_Result_-4852487533400575008">
      <data key="d0">Result</data>
      <data key="d1">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
      <data key="d3">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-722433886058403238">
      <data key="d0">Result</data>
      <data key="d1">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals</data>
      <data key="d3">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-1703645322827346362">
      <data key="d0">Result</data>
      <data key="d1">Perindopril was more potent weight-for-weight than enalapril</data>
      <data key="d3">Perindopril was more potent weight-for-weight than enalapril</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-5211224457821964713">
      <data key="d0">Result</data>
      <data key="d1">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
      <data key="d3">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="Compound_NITRENDIPINE">
      <data key="d0">Entity</data>
      <data key="d5">Compound</data>
      <data key="d6">NITRENDIPINE</data>
      <data key="d7">Nitrendipine</data>
    </node>
    <node id="PDF_11_Result_-3032712515991033099">
      <data key="d0">Result</data>
      <data key="d1">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
      <data key="d3">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-7933965937644750635">
      <data key="d0">Result</data>
      <data key="d1">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
      <data key="d3">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_596902998640378349">
      <data key="d0">Result</data>
      <data key="d1">Perindopril in- hibited and even prevented development of card- iac hypertrophy in the rat</data>
      <data key="d3">Perindopril in- hibited and even prevented development of card- iac hypertrophy in the rat</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_5632794443878813450">
      <data key="d0">Result</data>
      <data key="d1">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias.</data>
      <data key="d3">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_3716971167368789496">
      <data key="d0">Result</data>
      <data key="d1">Long term perindopril administra- tion either prevented or inhibited development of experimental cardiac hypertrophy</data>
      <data key="d3">Long term perindopril administra- tion either prevented or inhibited development of experimental cardiac hypertrophy</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_7798179061516336174">
      <data key="d0">Result</data>
      <data key="d1">Furthermore, perindopril normalised ex- perimentally induced prolongation of the action potential</data>
      <data key="d3">Furthermore, perindopril normalised ex- perimentally induced prolongation of the action potential</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_2437633947455976786">
      <data key="d0">Result</data>
      <data key="d1">Acute administration of perindopril shortly before coronary artery ligation in vivo significantly re- duced mortality and the severity of ventricular tachycardia and fibrillation</data>
      <data key="d3">Acute administration of perindopril shortly before coronary artery ligation in vivo significantly re- duced mortality and the severity of ventricular tachycardia and fibrillation</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_2488598613310986279">
      <data key="d0">Result</data>
      <data key="d1">Oral administration of single or repeated once daily doses of perindopril 1 to 16mg to normoten- sive subjects either had no significant effect on blood pressure or caused a slight, but significant, blood pressure decrease, particularly with higher doses</data>
      <data key="d3">Oral administration of single or repeated once daily doses of perindopril 1 to 16mg to normoten- sive subjects either had no significant effect on blood pressure or caused a slight, but significant, blood pressure decrease, particularly with higher doses</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_1730786705567194330">
      <data key="d0">Result</data>
      <data key="d1">Ajayi et al. (1986) found that a single oral dose of perindopril 8mg did not affect blood pressure and heart rate responses to dynamic exercise, fore- arm isometric exercise, the cold pressor test or Val- salva's manoeuvre, but enhanced the vagally me- diated sinus arrhythmia associated with deep breathing.</data>
      <data key="d3">Ajayi et al. (1986) found that a single oral dose of perindopril 8mg did not affect blood pressure and heart rate responses to dynamic exercise, fore- arm isometric exercise, the cold pressor test or Val- salva's manoeuvre, but enhanced the vagally me- diated sinus arrhythmia associated with deep breathing.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-2949242152273853589">
      <data key="d0">Result</data>
      <data key="d1">Single oral doses of perindopril 4, 8 and 16mg caused a dose-depend- ent increase in brachial and carotid artery diameter and blood flow with a decrease in forearm vascular resistance, as measured by the pulsed Doppler technique.</data>
      <data key="d3">Single oral doses of perindopril 4, 8 and 16mg caused a dose-depend- ent increase in brachial and carotid artery diameter and blood flow with a decrease in forearm vascular resistance, as measured by the pulsed Doppler technique.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-3828702804889172736">
      <data key="d0">Result</data>
      <data key="d1">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
      <data key="d3">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-3686212452926226249">
      <data key="d0">Result</data>
      <data key="d1">West et al. (1989) confirmed a perindopril-in- duced increase in parasympathetic tone in patients with essential hypertension, an effect which has also been noted in healthy subjects</data>
      <data key="d3">West et al. (1989) confirmed a perindopril-in- duced increase in parasympathetic tone in patients with essential hypertension, an effect which has also been noted in healthy subjects</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_3737680705182362017">
      <data key="d0">Result</data>
      <data key="d1">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
      <data key="d3">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_7094012108776873411">
      <data key="d0">Result</data>
      <data key="d1">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring</data>
      <data key="d3">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_6553828478640136841">
      <data key="d0">Result</data>
      <data key="d1">Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate.</data>
      <data key="d3">Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate.</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_7687329608720779505">
      <data key="d0">Result</data>
      <data key="d1">The blood pressure response to a single oral dose of perindopril 2mg has been compared with that of enalapril 2.5mg or captopril 6.25mg in a ran- domised double-blind study in 48 elderly patients with chronic cardiac failure</data>
      <data key="d3">The blood pressure response to a single oral dose of perindopril 2mg has been compared with that of enalapril 2.5mg or captopril 6.25mg in a ran- domised double-blind study in 48 elderly patients with chronic cardiac failure</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-2815337949325978627">
      <data key="d0">Result</data>
      <data key="d1">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
      <data key="d3">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_8498915914996141537">
      <data key="d0">Result</data>
      <data key="d1">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
      <data key="d3">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_-7769707290918879568">
      <data key="d0">Result</data>
      <data key="d1">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
      <data key="d3">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
      <data key="d4">PDF_11</data>
    </node>
    <node id="PDF_11_Result_8525444708222209317">
      <data key="d0">Result</data>
      <data key="d1">After administration of a single oral dose of per- indopril 8mg to 11 healthy subjects, 24-hour ur- inary output of sodium and chloride were in- creased by about 25% (p &lt; 0.02) and their renal clearance</data>
      <data key="d3">After administration of a single oral dose of per- indopril 8mg to 11 healthy subjects, 24-hour ur- inary output of sodium and chloride were in- creased by about 25% (p &lt; 0.02) and their renal clearance</data>
      <data key="d4">PDF_11</data>
    </node>
    <edge source="PDF_13" target="PDF_13_Result_-6969795018367777339">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_13" target="PDF_13_Result_-1840300504446391296">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_13" target="PDF_13_Conclusion_2175378491144090458">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_13_Result_-6969795018367777339" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">In the great majority of the study patients (more than 96%) perindopril was effective as monotherapy, achieving a significant reduction in both systolic and diastolic blood pressure, and in three-quarters of the study patients it normalized both systolic and diastolic blood pressure.</data>
    </edge>
    <edge source="PDF_13_Result_-1840300504446391296" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
    </edge>
    <edge source="PDF_13_Conclusion_2175378491144090458" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
    </edge>
    <edge source="PDF_13_Conclusion_2175378491144090458" target="Disease_ESSENTIAL HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
    </edge>
    <edge source="PDF_16" target="PDF_16_Result_-110396406922382148">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_16" target="PDF_16_Result_-3094613332956725653">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_16" target="PDF_16_Conclusion_660614483491161994">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_16_Result_-110396406922382148" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group (mean between-group difference 31.4 m, 95% confidence interval [CI] 10.8 to 51.9 m; p = 0.003).</data>
    </edge>
    <edge source="PDF_16_Result_-3094613332956725653" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">There was a significant impact on health-related quality of life: although the mean score for part 1 of the EQ-5D questionnaire deteriorated over time in the placebo group, quality of life was maintained in the perindopril group, for a between-group difference of 0.09 (p = 0.046).</data>
    </edge>
    <edge source="PDF_16_Conclusion_660614483491161994" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
    </edge>
    <edge source="PDF_15" target="PDF_15_Method_7208700364633966312">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_15" target="PDF_15_Result_6873332449068391565">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_15" target="PDF_15_Result_5078306612820016528">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_15" target="PDF_15_Result_696242867850604664">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_15" target="PDF_15_Conclusion_-4354921419621582139">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_15_Method_7208700364633966312" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The study used a multicentre, randomised, placebo-controlled, parallel group design to evaluate the antihypertensive efficacy of perindopril in an elderly hypertensive population.</data>
    </edge>
    <edge source="PDF_15_Result_6873332449068391565" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P &lt; 0.01 vs placebo).</data>
    </edge>
    <edge source="PDF_15_Result_5078306612820016528" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg.</data>
    </edge>
    <edge source="PDF_15_Result_696242867850604664" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Successful treatment, defined as supine diastolic BP &lt;90 mm Hg or &gt;10 mm Hg decrease from baseline at end of treatment was significantly (P = 0.014) higher on perindopril (60%) compared to placebo (44%).</data>
    </edge>
    <edge source="PDF_15_Conclusion_-4354921419621582139" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
    </edge>
    <edge source="PDF_8" target="PDF_8_Hypothesis_3044518278249807850">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_8" target="PDF_8_Method_1090791868839956195">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_8" target="PDF_8_Result_7006409746140902161">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_8_Hypothesis_3044518278249807850" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
    </edge>
    <edge source="PDF_8_Hypothesis_3044518278249807850" target="Disease_TYPE 2 DIABETES MELLITUS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
    </edge>
    <edge source="PDF_8_Method_1090791868839956195" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">The stability of the GLP-1/peptide 1 complex was investigated, and the physiological functions of the GLP-1/peptide 1 complex were compared to those of exenatide and liraglutide in animals.</data>
    </edge>
    <edge source="PDF_8_Method_1090791868839956195" target="Compound_EXENATIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The stability of the GLP-1/peptide 1 complex was investigated, and the physiological functions of the GLP-1/peptide 1 complex were compared to those of exenatide and liraglutide in animals.</data>
    </edge>
    <edge source="PDF_8_Method_1090791868839956195" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The stability of the GLP-1/peptide 1 complex was investigated, and the physiological functions of the GLP-1/peptide 1 complex were compared to those of exenatide and liraglutide in animals.</data>
    </edge>
    <edge source="PDF_8_Result_7006409746140902161" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1/peptide 1 complex remarkably raised the half-life of GLP-1 in vivo and showed better glucose tolerance and higher HbA1c reduction than exenatide and liraglutide in rodents.</data>
    </edge>
    <edge source="PDF_8_Result_7006409746140902161" target="Compound_EXENATIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1/peptide 1 complex remarkably raised the half-life of GLP-1 in vivo and showed better glucose tolerance and higher HbA1c reduction than exenatide and liraglutide in rodents.</data>
    </edge>
    <edge source="PDF_8_Result_7006409746140902161" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1/peptide 1 complex remarkably raised the half-life of GLP-1 in vivo and showed better glucose tolerance and higher HbA1c reduction than exenatide and liraglutide in rodents.</data>
    </edge>
    <edge source="PDF_19" target="PDF_19_Hypothesis_-2602979087861542700">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_19" target="PDF_19_Method_-4736383758653828058">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_19" target="PDF_19_Result_-1189977786821166082">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_19" target="PDF_19_Result_-1548407765133182630">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_19" target="PDF_19_Conclusion_9036677103515943065">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_19_Hypothesis_-2602979087861542700" target="Compound_CFCHPS">
      <data key="d8">MENTIONS</data>
      <data key="d9">lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs</data>
    </edge>
    <edge source="PDF_19_Result_-1189977786821166082" target="Gene_DNA">
      <data key="d8">MENTIONS</data>
      <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction.</data>
    </edge>
    <edge source="PDF_19_Conclusion_9036677103515943065" target="Compound_CFCHPS">
      <data key="d8">MENTIONS</data>
      <data key="d9">cfChPs may act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
    </edge>
    <edge source="PDF_17" target="PDF_17_Result_-5583964824094673079">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_17" target="PDF_17_Conclusion_-8096456597440705116">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_17" target="PDF_17_Result_2918214787836327464">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_17" target="PDF_17_Result_5593485977643258687">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_17" target="PDF_17_Conclusion_-886874052167900569">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_17_Conclusion_-8096456597440705116" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
    </edge>
    <edge source="PDF_17_Result_2918214787836327464" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Patients randomly assigned to perindopril significantly improved their mean walking distance compared with those in the placebo group (p &lt; 0.001) with a mean increase of 37 m in the mean walking distance at 10 weeks.</data>
    </edge>
    <edge source="PDF_17_Result_5593485977643258687" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril improved the walking distance in both the less symptomatic (NYHA I or II) and the more symptomatic patients (NYHA III or IV).</data>
    </edge>
    <edge source="PDF_17_Conclusion_-886874052167900569" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">This study provides a powerful evidence base to justify the widespread use of ACE inhibitors even in very old patients with left ventricular systolic dysfunction.</data>
    </edge>
    <edge source="PDF_1" target="PDF_1_Result_3142213223919009091">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_1" target="PDF_1_Result_4139653914714409106">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_1" target="PDF_1_Result_8944576178123360759">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_1" target="PDF_1_Result_8734249471022747097">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_1" target="PDF_1_Result_3939344856950814862">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_1" target="PDF_1_Result_7134815922756028491">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_1_Result_3142213223919009091" target="Protein_HBA1C">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
    </edge>
    <edge source="PDF_1_Result_3142213223919009091" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
    </edge>
    <edge source="PDF_1_Result_3142213223919009091" target="Compound_DAPAGLIFLOZIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
    </edge>
    <edge source="PDF_1_Result_3142213223919009091" target="Disease_SIDD">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
    </edge>
    <edge source="PDF_1_Result_4139653914714409106" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin</data>
    </edge>
    <edge source="PDF_1_Result_4139653914714409106" target="Compound_DAPAGLIFLOZIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin</data>
    </edge>
    <edge source="PDF_1_Result_8944576178123360759" target="Compound_DAPAGLIFLOZIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment</data>
    </edge>
    <edge source="PDF_1_Result_8944576178123360759" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment</data>
    </edge>
    <edge source="PDF_1_Result_8944576178123360759" target="Process_INSULIN RESISTANCE">
      <data key="d8">MENTIONS</data>
      <data key="d9">dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment</data>
    </edge>
    <edge source="PDF_1_Result_8734249471022747097" target="Compound_DAPAGLIFLOZIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD</data>
    </edge>
    <edge source="PDF_1_Result_8734249471022747097" target="Disease_SIDD">
      <data key="d8">MENTIONS</data>
      <data key="d9">dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD</data>
    </edge>
    <edge source="PDF_1_Result_8734249471022747097" target="Disease_SIRD">
      <data key="d8">MENTIONS</data>
      <data key="d9">dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD</data>
    </edge>
    <edge source="PDF_1_Result_3939344856950814862" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">semaglutide resulted in a larger improvement in patient-reported treatment satisfaction compared with dapagliflozin, particularly in the SIDD group</data>
    </edge>
    <edge source="PDF_1_Result_3939344856950814862" target="Compound_DAPAGLIFLOZIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">semaglutide resulted in a larger improvement in patient-reported treatment satisfaction compared with dapagliflozin, particularly in the SIDD group</data>
    </edge>
    <edge source="PDF_1_Result_3939344856950814862" target="Disease_SIDD">
      <data key="d8">MENTIONS</data>
      <data key="d9">semaglutide resulted in a larger improvement in patient-reported treatment satisfaction compared with dapagliflozin, particularly in the SIDD group</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Hypothesis_5697665869451186234">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Method_-1807004228531522170">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_5355102210480636028">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_8938251966814938440">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_-7406637995227342214">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_-3492516078220279717">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_-5523756741762429381">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_889410764312178502">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Result_-7866815614096464297">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20" target="PDF_20_Conclusion_-8909461333127802831">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_20_Hypothesis_5697665869451186234" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">resveratrol may preserve cognitive and mood function in old age by mitigating age-related changes in the hippocampus</data>
    </edge>
    <edge source="PDF_20_Method_-1807004228531522170" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">examined the efficacy of resveratrol for counteracting age-related memory and mood impairments and the associated detrimental changes in the hippocampus in male F344 rats</data>
    </edge>
    <edge source="PDF_20_Result_5355102210480636028" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment in late middle age improved ability for spatial learning and spatial memory formation at an advanced age</data>
    </edge>
    <edge source="PDF_20_Result_8938251966814938440" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment improved mood function in aged rats</data>
    </edge>
    <edge source="PDF_20_Result_-7406637995227342214" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats</data>
    </edge>
    <edge source="PDF_20_Result_-3492516078220279717" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods</data>
    </edge>
    <edge source="PDF_20_Result_-5523756741762429381" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment enhanced microvasculature in the hippocampus of aged rats</data>
    </edge>
    <edge source="PDF_20_Result_889410764312178502" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment reduced the hypertrophy of astrocytes in aged rats</data>
    </edge>
    <edge source="PDF_20_Result_-7866815614096464297" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment reduced activation of microglia in aged rats</data>
    </edge>
    <edge source="PDF_20_Conclusion_-8909461333127802831" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RESV treatment in late middle age can positively modulate the structure and function of the aged hippocampus</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Result_1509227847411498697">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Conclusion_-8089193946421374005">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Result_-5221652143066512179">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Result_685452967745399653">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Result_-6785829855875291712">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Result_-934001866393829912">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6" target="PDF_6_Result_4648188858690542777">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_6_Result_-5221652143066512179" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
    </edge>
    <edge source="PDF_6_Result_685452967745399653" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo (P&lt;0.001; Table 3), constituting a -5.1% (3.0) relative change from baseline.</data>
    </edge>
    <edge source="PDF_6_Result_-6785829855875291712" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Daily insulin use was reduced by 11.3 units [-23.6, -4.9] with semaglutide compared to placebo (P&lt;0.001; Table 2).</data>
    </edge>
    <edge source="PDF_6_Result_-934001866393829912" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Daily carbohydrate intake (as entered into the participants' bolus calculator) was also reduced by 36 g [-55, -15] with semaglutide compared to placebo (P&lt;0.001).</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Hypothesis_1839083106408537623">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Method_-8182141859335369411">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Method_-1811185656356958275">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Method_4583438222083563541">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Method_974516171928313980">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Method_-6761575539062862121">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Method_-1111586005617789482">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Result_-8646250785302555436">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Result_8483513546146417652">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Result_-76489948366614969">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Conclusion_4816139841263321359">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9" target="PDF_9_Conclusion_-3030786454116916093">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_9_Hypothesis_1839083106408537623" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">IDO1 inhibitory activity could be the result of undesirable side reactions instead of selective binding to IDO1.</data>
    </edge>
    <edge source="PDF_9_Method_-8182141859335369411" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">IDO1 inhibition determined using purified ferric IDO1 reduced by ascorbic acid, necessitating methylene blue as electron carrier.</data>
    </edge>
    <edge source="PDF_9_Method_-1811185656356958275" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">IDO1 inhibition determined using cytochrome P450 reductase/NADPH and cytochrome b5 as reductants.</data>
    </edge>
    <edge source="PDF_9_Method_4583438222083563541" target="Compound_L-TRP">
      <data key="d8">MENTIONS</data>
      <data key="d9">The amount of L-Trp breakdown monitored by HPLC after stopping the enzymatic reaction by acidification and hydrolysis of NFK to kynurenine at 50 °C.</data>
    </edge>
    <edge source="PDF_9_Method_4583438222083563541" target="Compound_KYNURENINE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The amount of L-Trp breakdown monitored by HPLC after stopping the enzymatic reaction by acidification and hydrolysis of NFK to kynurenine at 50 °C.</data>
    </edge>
    <edge source="PDF_9_Method_4583438222083563541" target="Compound_NFK">
      <data key="d8">MENTIONS</data>
      <data key="d9">The amount of L-Trp breakdown monitored by HPLC after stopping the enzymatic reaction by acidification and hydrolysis of NFK to kynurenine at 50 °C.</data>
    </edge>
    <edge source="PDF_9_Method_974516171928313980" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">IDO1 inhibitors discovered by natural product screening, structure-based drug design, or in the majority of cases by high throughput screening (HTS).</data>
    </edge>
    <edge source="PDF_9_Method_-6761575539062862121" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">Cellular mIDO2 inhibition screen of 640 FDA-approved compounds yielded 43 hits that were subsequently also tested on IDO1.</data>
    </edge>
    <edge source="PDF_9_Method_-6761575539062862121" target="Protein_IDO2">
      <data key="d8">MENTIONS</data>
      <data key="d9">Cellular mIDO2 inhibition screen of 640 FDA-approved compounds yielded 43 hits that were subsequently also tested on IDO1.</data>
    </edge>
    <edge source="PDF_9_Method_-1111586005617789482" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">IDO1 inhibitors discovered via yeast growth assay</data>
    </edge>
    <edge source="PDF_9_Result_-8646250785302555436" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
    </edge>
    <edge source="PDF_9_Result_-8646250785302555436" target="Compound_EBSELEN">
      <data key="d8">MENTIONS</data>
      <data key="d9">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1 from 404 to 411 nm.</data>
    </edge>
    <edge source="PDF_9_Result_8483513546146417652" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">IDO1 inhibitory properties have been attributed to thousands of compounds according to the scientific and patent literature.</data>
    </edge>
    <edge source="PDF_9_Conclusion_-3030786454116916093" target="Protein_IDO1">
      <data key="d8">MENTIONS</data>
      <data key="d9">The phenylimidazole scaffold provides a promising starting point for the development of IDO1 inhibitors, as its binding mode to the active site is known through X-ray crystallography.</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Hypothesis_9079035788419069742">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Method_451804169188668694">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Result_6138634157418763559">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Result_169181898259998290">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Result_-5898660160653364919">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Result_8108736170855866172">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Conclusion_-7700792071022539550">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Conclusion_3138895423587022325">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18" target="PDF_18_Conclusion_-2483027973675422084">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_18_Hypothesis_9079035788419069742" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">We hypothesize that long-term supplementation with an intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects the health and lifespan of the grey mouse lemur (Microcebus murinus).</data>
    </edge>
    <edge source="PDF_18_Method_451804169188668694" target="Gene_MICROCEBUS MURINUS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
    </edge>
    <edge source="PDF_18_Method_451804169188668694" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs (Microcebus murinus, N = 33), all receiving 105 kJ/day of food but with a subset of 18 animals receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
    </edge>
    <edge source="PDF_18_Result_6138634157418763559" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">RSV supplementation improved cognitive and motor performance at middle age as compared to control (CTL) animals.</data>
    </edge>
    <edge source="PDF_18_Result_169181898259998290" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
    </edge>
    <edge source="PDF_18_Result_-5898660160653364919" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
    </edge>
    <edge source="PDF_18_Result_8108736170855866172" target="Disease_CANCER">
      <data key="d8">MENTIONS</data>
      <data key="d9">Incidence of age-related pathologies such as cancer and chronic nephritis was not significantly changed by RSV supplementation</data>
    </edge>
    <edge source="PDF_18_Result_8108736170855866172" target="Disease_NEPHRITIS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Incidence of age-related pathologies such as cancer and chronic nephritis was not significantly changed by RSV supplementation</data>
    </edge>
    <edge source="PDF_18_Result_8108736170855866172" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Incidence of age-related pathologies such as cancer and chronic nephritis was not significantly changed by RSV supplementation</data>
    </edge>
    <edge source="PDF_18_Conclusion_-7700792071022539550" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
    </edge>
    <edge source="PDF_18_Conclusion_3138895423587022325" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">very long-term RSV supplementation results in health benefits at middle-age in male mouse lemurs, as demonstrated here for motor and cognitive capacities, but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
    </edge>
    <edge source="PDF_18_Conclusion_-2483027973675422084" target="Compound_RESVERATROL">
      <data key="d8">MENTIONS</data>
      <data key="d9">long-term RSV supplementation does not mimic the lifespan extension provided by chronic CR, and does not reduce either the risk of age-associated diseases or age-associated mortality.</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Hypothesis_-8297886518736926679">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Method_-4517108383457012009">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_-4308519927738533622">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_8453552442843427402">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_4299364976257756467">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_5074024079918988038">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_-1674698398303613927">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_7536818821284748040">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_-3809630368760752699">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Result_-1948915980787463556">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2" target="PDF_2_Conclusion_4539983027530505413">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_2_Hypothesis_-8297886518736926679" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
    </edge>
    <edge source="PDF_2_Method_-4517108383457012009" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Diet-induced obese (DIO) mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated.</data>
    </edge>
    <edge source="PDF_2_Result_-4308519927738533622" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
    </edge>
    <edge source="PDF_2_Result_8453552442843427402" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide transiently reduced dark phase EE until day 6 of treatment, after which levels were not significantly lower than those of the vehicle-treated controls.</data>
    </edge>
    <edge source="PDF_2_Result_4299364976257756467" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The reduction in energy intake was driven by decreased chocolate intake with semaglutide treatment compared with vehicle.</data>
    </edge>
    <edge source="PDF_2_Result_5074024079918988038" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide specifically accesses GLP-1R-positive brain areas following peripheral administration.</data>
    </edge>
    <edge source="PDF_2_Result_5074024079918988038" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide specifically accesses GLP-1R-positive brain areas following peripheral administration.</data>
    </edge>
    <edge source="PDF_2_Result_-1674698398303613927" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1R expression in rat tissue was detected within tanycytes, neuronal perikarya, and dendrites, with more limited staining in  tanycytes.</data>
    </edge>
    <edge source="PDF_2_Result_7536818821284748040" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide does not interact with endothelial cells of the BBB.</data>
    </edge>
    <edge source="PDF_2_Result_-3809630368760752699" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1R was coexpressed with CART in the ARH but not in the AP or NTS.</data>
    </edge>
    <edge source="PDF_2_Result_-3809630368760752699" target="Gene_CART">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1R was coexpressed with CART in the ARH but not in the AP or NTS.</data>
    </edge>
    <edge source="PDF_2_Result_-1948915980787463556" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis (BST), central amygdala nucleus (CeA), OV, parasubthalamic nucleus (PSTN), SFO, midline group of the dorsal thalamus (MTN), PB, AP, DMX, and NTS after acute s.c. semaglutide (4 hours).</data>
    </edge>
    <edge source="PDF_2_Conclusion_4539983027530505413" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">We suggest semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
    </edge>
    <edge source="PDF_2_Conclusion_4539983027530505413" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">We suggest semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Hypothesis_-377144521760521173">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Method_3069679492984245994">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Method_-3886734006662591511">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Result_-4458030266816943244">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Result_1276167620882736574">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Result_4145573934341478012">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Result_8527041239487712763">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Result_-4160943347152761472">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Result_1933072671520032081">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10" target="PDF_10_Conclusion_-377144521760521173">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_10_Hypothesis_-377144521760521173" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Hypothesis_-377144521760521173" target="Gene_POMC">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Hypothesis_-377144521760521173" target="Gene_CART">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Hypothesis_-377144521760521173" target="Process_ARC">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Hypothesis_-377144521760521173" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Method_3069679492984245994" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Peripheral injection of fluorescently labeled liraglutide in mice</data>
    </edge>
    <edge source="PDF_10_Result_-4458030266816943244" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide does not activate GLP-1-producing neurons in the hindbrain.</data>
    </edge>
    <edge source="PDF_10_Result_-4458030266816943244" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide does not activate GLP-1-producing neurons in the hindbrain.</data>
    </edge>
    <edge source="PDF_10_Result_1276167620882736574" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
    </edge>
    <edge source="PDF_10_Result_1276167620882736574" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus.</data>
    </edge>
    <edge source="PDF_10_Result_4145573934341478012" target="Process_ARC">
      <data key="d8">MENTIONS</data>
      <data key="d9">Labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
    </edge>
    <edge source="PDF_10_Result_4145573934341478012" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus.</data>
    </edge>
    <edge source="PDF_10_Result_8527041239487712763" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
    </edge>
    <edge source="PDF_10_Result_8527041239487712763" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r-/- mice.</data>
    </edge>
    <edge source="PDF_10_Result_-4160943347152761472" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) in the ARC.</data>
    </edge>
    <edge source="PDF_10_Result_-4160943347152761472" target="Gene_POMC">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) in the ARC.</data>
    </edge>
    <edge source="PDF_10_Result_-4160943347152761472" target="Gene_CART">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) in the ARC.</data>
    </edge>
    <edge source="PDF_10_Result_-4160943347152761472" target="Process_ARC">
      <data key="d8">MENTIONS</data>
      <data key="d9">Liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) in the ARC.</data>
    </edge>
    <edge source="PDF_10_Result_1933072671520032081" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
    </edge>
    <edge source="PDF_10_Result_1933072671520032081" target="Gene_POMC">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
    </edge>
    <edge source="PDF_10_Result_1933072671520032081" target="Gene_CART">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
    </edge>
    <edge source="PDF_10_Result_1933072671520032081" target="Gene_NPY">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
    </edge>
    <edge source="PDF_10_Result_1933072671520032081" target="Gene_AGRP">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
    </edge>
    <edge source="PDF_10_Result_1933072671520032081" target="Compound_GABA">
      <data key="d8">MENTIONS</data>
      <data key="d9">GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
    </edge>
    <edge source="PDF_10_Conclusion_-377144521760521173" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Conclusion_-377144521760521173" target="Gene_POMC">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Conclusion_-377144521760521173" target="Gene_CART">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Conclusion_-377144521760521173" target="Process_ARC">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_10_Conclusion_-377144521760521173" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_4202519547059753600">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_-7151319057790118606">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_-1494737022746030875">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_809844039502751496">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_-152863557928388820">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_-7534957547168955468">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_-8234881479684600874">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_6786663891860836604">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Result_-8827963784690564189">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Conclusion_-6230425390282510934">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7" target="PDF_7_Hypothesis_-6851688615719123305">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_CRP">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_LEPTIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_ADIPONECTIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_GHRELIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_IGFBP">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_GHR">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_NCAM1">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_-1494737022746030875" target="Protein_UNC5D">
      <data key="d8">MENTIONS</data>
      <data key="d9">Several of the proteins identified in STEP 1 and STEP 2 are known to be related to obesity and T2D pathophysiology and their associated complications, including C-reactive protein (CRP), adipokines (leptin, adiponectin), ghrelin, insulin-like growth factor binding protein (IGFBP), growth hormonereceptor (GHR), neuralcelladhesionmolecule 1 (NCAM1) and netrin receptor (UNC5D), among others.</data>
    </edge>
    <edge source="PDF_7_Result_809844039502751496" target="Protein_MTORC1">
      <data key="d8">MENTIONS</data>
      <data key="d9">Protein set analyses found that semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
    </edge>
    <edge source="PDF_7_Result_-8234881479684600874" target="Protein_TENASCIN C">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
    </edge>
    <edge source="PDF_7_Result_-8234881479684600874" target="Protein_NT-PROBNP">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
    </edge>
    <edge source="PDF_7_Result_-8234881479684600874" target="Protein_THROMBOSPONDIN 2">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
    </edge>
    <edge source="PDF_7_Result_-8234881479684600874" target="Protein_CD93">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
    </edge>
    <edge source="PDF_7_Result_-8234881479684600874" target="Protein_MSR1">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
    </edge>
    <edge source="PDF_7_Result_-8234881479684600874" target="Protein_ANGPT2">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extracellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_-8915218293332595416">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Conclusion_5692981340058967712">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_-7269795294449655842">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_-7758215992716246093">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_7546556218369098929">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_-4843215839429067794">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_5581553987613849359">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_1626576483297861981">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14" target="PDF_14_Result_69690161036949378">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_14_Result_-8915218293332595416" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
    </edge>
    <edge source="PDF_14_Result_-8915218293332595416" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
    </edge>
    <edge source="PDF_14_Result_-8915218293332595416" target="Disease_MYOCARDIAL INFARCTION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
    </edge>
    <edge source="PDF_14_Result_-8915218293332595416" target="Disease_STROKE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
    </edge>
    <edge source="PDF_14_Result_-8915218293332595416" target="Process_MORTALITY">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
    </edge>
    <edge source="PDF_14_Conclusion_5692981340058967712" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
    </edge>
    <edge source="PDF_14_Conclusion_5692981340058967712" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
    </edge>
    <edge source="PDF_14_Result_-7269795294449655842" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effect size for perindopril alone was larger than that of the combined ACEI analysis.</data>
    </edge>
    <edge source="PDF_14_Result_-7269795294449655842" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effect size for perindopril alone was larger than that of the combined ACEI analysis.</data>
    </edge>
    <edge source="PDF_14_Result_-7758215992716246093" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
    </edge>
    <edge source="PDF_14_Result_-7758215992716246093" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p &lt; 0.0001) when compared to the overall ACEI effect.</data>
    </edge>
    <edge source="PDF_14_Result_7546556218369098929" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039)</data>
    </edge>
    <edge source="PDF_14_Result_7546556218369098929" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039)</data>
    </edge>
    <edge source="PDF_14_Result_-4843215839429067794" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
    </edge>
    <edge source="PDF_14_Result_-4843215839429067794" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p &lt; 0.0001). This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p &lt; 0.0001).</data>
    </edge>
    <edge source="PDF_14_Result_5581553987613849359" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effect of perindopril on stroke demonstrated a highly significant reduction in event rate (OR 0.79; 95% CI: 0.72-0.86; p &lt; 0.0001). However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287)</data>
    </edge>
    <edge source="PDF_14_Result_5581553987613849359" target="Disease_STROKE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effect of perindopril on stroke demonstrated a highly significant reduction in event rate (OR 0.79; 95% CI: 0.72-0.86; p &lt; 0.0001). However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287)</data>
    </edge>
    <edge source="PDF_14_Result_5581553987613849359" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effect of perindopril on stroke demonstrated a highly significant reduction in event rate (OR 0.79; 95% CI: 0.72-0.86; p &lt; 0.0001). However, the exclusion of perindopril trials from the other ACEI trials reproduced a non-significant reduction in stroke events (OR 1.05; p = 0.1287)</data>
    </edge>
    <edge source="PDF_14_Result_1626576483297861981" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008)</data>
    </edge>
    <edge source="PDF_14_Result_69690161036949378" target="Compound_ACE INHIBITORS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92-0.98; p = 0.0033).</data>
    </edge>
    <edge source="PDF_14_Result_69690161036949378" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92-0.98; p = 0.0033).</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Hypothesis_6221589398331814564">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Method_-2129798450090827598">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Method_5057154544204677720">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Method_771869393751147769">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Method_599907980140553093">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_-299893572724238923">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_8850959385062359021">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_923860893507256371">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_2820051245537628533">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_1621174394233847305">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_2502046257461297142">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Result_5985350942412134511">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Conclusion_1929525825689517844">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Conclusion_8337216335006696470">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3" target="PDF_3_Conclusion_3130345879434505383">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_3_Hypothesis_6221589398331814564" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
    </edge>
    <edge source="PDF_3_Hypothesis_6221589398331814564" target="Gene_PPG">
      <data key="d8">MENTIONS</data>
      <data key="d9">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
    </edge>
    <edge source="PDF_3_Method_-2129798450090827598" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
    </edge>
    <edge source="PDF_3_Method_-2129798450090827598" target="Protein_DTA">
      <data key="d8">MENTIONS</data>
      <data key="d9">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
    </edge>
    <edge source="PDF_3_Method_5057154544204677720" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">chemogenetic inhibition of PPGNTS neurons on termination of large solid and liquid meals, using the inhibitory hM4Di Designer Receptor Exclusively Activated by Designer Drugs (DREADD)</data>
    </edge>
    <edge source="PDF_3_Method_771869393751147769" target="Gene_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice</data>
    </edge>
    <edge source="PDF_3_Method_599907980140553093" target="Gene_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
    </edge>
    <edge source="PDF_3_Method_599907980140553093" target="Gene_OXTR">
      <data key="d8">MENTIONS</data>
      <data key="d9">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
    </edge>
    <edge source="PDF_3_Result_-299893572724238923" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">chemogenetic activation of PPGNTS neurons activated 82% of transduced neurons</data>
    </edge>
    <edge source="PDF_3_Result_8850959385062359021" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
    </edge>
    <edge source="PDF_3_Result_923860893507256371" target="Gene_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
    </edge>
    <edge source="PDF_3_Result_2820051245537628533" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
    </edge>
    <edge source="PDF_3_Result_2820051245537628533" target="Gene_OXTR">
      <data key="d8">MENTIONS</data>
      <data key="d9">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
    </edge>
    <edge source="PDF_3_Result_1621174394233847305" target="Protein_OXYTOCIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
    </edge>
    <edge source="PDF_3_Result_1621174394233847305" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Superfusion of oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
    </edge>
    <edge source="PDF_3_Result_2502046257461297142" target="Protein_OXYTOCIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">While oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
    </edge>
    <edge source="PDF_3_Result_2502046257461297142" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">While oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
    </edge>
    <edge source="PDF_3_Result_2502046257461297142" target="Protein_DTA">
      <data key="d8">MENTIONS</data>
      <data key="d9">While oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
    </edge>
    <edge source="PDF_3_Result_5985350942412134511" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
    </edge>
    <edge source="PDF_3_Result_5985350942412134511" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
    </edge>
    <edge source="PDF_3_Conclusion_1929525825689517844" target="Protein_GLP-1">
      <data key="d8">MENTIONS</data>
      <data key="d9">central and peripheral GLP-1 systems suppress eating via independent gut-brain circuits</data>
    </edge>
    <edge source="PDF_3_Conclusion_8337216335006696470" target="Gene_OXTR">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
    </edge>
    <edge source="PDF_3_Conclusion_8337216335006696470" target="Gene_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
    </edge>
    <edge source="PDF_3_Conclusion_8337216335006696470" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
    </edge>
    <edge source="PDF_3_Conclusion_3130345879434505383" target="Gene_PPGNTS">
      <data key="d8">MENTIONS</data>
      <data key="d9">PPGNTS neurons are not recruited by peripherally administered semaglutide, or required for the anorexigenic effects of liraglutide or semaglutide, and concurrent activation of PPGNTS neurons augments semaglutide-induced eating suppression</data>
    </edge>
    <edge source="PDF_3_Conclusion_3130345879434505383" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">PPGNTS neurons are not recruited by peripherally administered semaglutide, or required for the anorexigenic effects of liraglutide or semaglutide, and concurrent activation of PPGNTS neurons augments semaglutide-induced eating suppression</data>
    </edge>
    <edge source="PDF_3_Conclusion_3130345879434505383" target="Compound_LIRAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">PPGNTS neurons are not recruited by peripherally administered semaglutide, or required for the anorexigenic effects of liraglutide or semaglutide, and concurrent activation of PPGNTS neurons augments semaglutide-induced eating suppression</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-7309760128306513036">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_1472442981486919918">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-3085720973791383362">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_2254116346577049562">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-1177706342943020559">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-4682530704327295254">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_684292181619973767">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-3398238003419588495">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_2629134144249230609">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_3585129967545597750">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-7560771698952097683">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4" target="PDF_4_Result_-6836731396123171278">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_4_Result_-7309760128306513036" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.</data>
    </edge>
    <edge source="PDF_4_Result_1472442981486919918" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%), waist circumference (-7.7 cm) and waist-to-height ratio (-6.9%) versus placebo (-1.5%, -1.3 cm and -1.0%, respectively; P &lt; 0.0001 for all comparisons versus placebo).</data>
    </edge>
    <edge source="PDF_4_Result_-3085720973791383362" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide was associated with fewer serious adverse events.</data>
    </edge>
    <edge source="PDF_4_Result_2254116346577049562" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">At week 208, mean weight loss in the semaglutide group analyzed as first on-treatment was -11.7% compared with -1.5% for the placebo group.</data>
    </edge>
    <edge source="PDF_4_Result_-1177706342943020559" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Among in-trial (intention-to-treat principle) patients at week 104, weight loss of≥5%, ≥10%, ≥15%, ≥20% and ≥25% was achieved by 67.8%, 44.2%, 22.9%, 11.0% and 4.9%, respectively, of those treated with semaglutide compared with 21.3%, 6.9%, 1.7%, 0.6% and 0.1% of those receiving placebo.</data>
    </edge>
    <edge source="PDF_4_Result_-4682530704327295254" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">At week 208, average reduction in WC was -7.7 cm with semaglutide versus -1.3 cm with placebo, with a treatment difference of -6.4 cm (95% CI-7.18 to-5.61; P&lt;0.0001)21.</data>
    </edge>
    <edge source="PDF_4_Result_684292181619973767" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">At week 208, in the group randomized to semaglutide, there was a relative reduction of 6.9% in WHtR compared with 1.0% in placebo (treatment difference -5.87% points; 95% CI-6.56 to-5.17; P&lt;0.0001).</data>
    </edge>
    <edge source="PDF_4_Result_-3398238003419588495" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">At week 104, 52.4% of patients treated with semaglutide achieved improvement in BMI category compared with 15.7% of those receiving placebo.</data>
    </edge>
    <edge source="PDF_4_Result_2629134144249230609" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">In the semaglutide group, 12.0% of patients achieved a BMI&lt;25 kg m¯², which is considered the healthy BMI category, compared with 1.2% for placebo; per study inclusion criteria, no patients were in this category at baseline.</data>
    </edge>
    <edge source="PDF_4_Result_3585129967545597750" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Women had a greater difference in mean weight loss with semaglutide versus placebo (-11.1% (95% CI -11.56 to -10.66) versus -7.5% in men (95% CI -7.78 to -7.23); P &lt; 0.0001).</data>
    </edge>
    <edge source="PDF_4_Result_-7560771698952097683" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">For lower BMI classes, discontinuation rates are higher in the semaglutide group but not the placebo group.</data>
    </edge>
    <edge source="PDF_4_Result_-6836731396123171278" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide was associated with lower SAEs, primarily driven by CV event and infections.</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Hypothesis_-8856319259921474255">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Method_-2436680410126177391">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_2710636421122754870">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_-4141003330907677127">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_-1002101900670632989">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_-4412264048747100113">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_-7938757989094910463">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_8878235989260343804">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_4864384080983545575">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_4028748785160573470">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_860370958687953436">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_-8661222603736243328">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_426357961769712333">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Result_7791270865785449861">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Conclusion_-1586288735173776015">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5" target="PDF_5_Conclusion_8037783431905148000">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_5_Hypothesis_-8856319259921474255" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">We investigated the therapeutic efficacy of the GLP-1R agonist semaglutide in a mouse model of INAD.</data>
    </edge>
    <edge source="PDF_5_Hypothesis_-8856319259921474255" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">We investigated the therapeutic efficacy of the GLP-1R agonist semaglutide in a mouse model of INAD.</data>
    </edge>
    <edge source="PDF_5_Hypothesis_-8856319259921474255" target="Disease_INAD">
      <data key="d8">MENTIONS</data>
      <data key="d9">We investigated the therapeutic efficacy of the GLP-1R agonist semaglutide in a mouse model of INAD.</data>
    </edge>
    <edge source="PDF_5_Method_-2436680410126177391" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
    </edge>
    <edge source="PDF_5_Method_-2436680410126177391" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The Pla2g6-inad knock-in mouse model (Pla2g6-/-) was administered with semaglutide at three doses; 0.5 µg/g, 0.25 µg/g or 0.15 µg/g, via intraperitoneal injection once a week.</data>
    </edge>
    <edge source="PDF_5_Result_2710636421122754870" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice.</data>
    </edge>
    <edge source="PDF_5_Result_2710636421122754870" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">A significant increase in survival was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide, with median survival at 129 days vs 99 days for untreated Pla2g6¯¹- mice.</data>
    </edge>
    <edge source="PDF_5_Result_-4141003330907677127" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
    </edge>
    <edge source="PDF_5_Result_-4141003330907677127" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Pla2g6-/- mice treated with 0.5 µg/g semaglutide did not show a significant deficit in rotarod performance compared to wild-type controls at any time point measured.</data>
    </edge>
    <edge source="PDF_5_Result_-1002101900670632989" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
    </edge>
    <edge source="PDF_5_Result_-1002101900670632989" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Treatment of Pla2g6-¹- mice with 0.5 µg/g semaglutide resulted in a significant improvement in performance of the vertical pole test compared to untreated mice from week 9 to week 13</data>
    </edge>
    <edge source="PDF_5_Result_-4412264048747100113" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
    </edge>
    <edge source="PDF_5_Result_-4412264048747100113" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
    </edge>
    <edge source="PDF_5_Result_-4412264048747100113" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">A significant increase in GLP-1R expression was observed in Pla2g6-¹- mice treated with 0.5 µg/g semaglutide at 14 weeks when compared to age-matched wild-type and untreated Pla2g6¯¹- controls</data>
    </edge>
    <edge source="PDF_5_Result_-7938757989094910463" target="Protein_CD68">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-¹- mice.</data>
    </edge>
    <edge source="PDF_5_Result_-7938757989094910463" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-¹- mice.</data>
    </edge>
    <edge source="PDF_5_Result_-7938757989094910463" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-¹- mice.</data>
    </edge>
    <edge source="PDF_5_Result_8878235989260343804" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-¹- controls.</data>
    </edge>
    <edge source="PDF_5_Result_8878235989260343804" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-¹- controls.</data>
    </edge>
    <edge source="PDF_5_Result_4864384080983545575" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-¹- mice in the cortex</data>
    </edge>
    <edge source="PDF_5_Result_4864384080983545575" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-¹- mice in the cortex</data>
    </edge>
    <edge source="PDF_5_Result_4028748785160573470" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Treatment with semaglutide resulted in up-regulation of GLP-1R expression suggesting a feed-back loop upon activation of the receptor.</data>
    </edge>
    <edge source="PDF_5_Result_4028748785160573470" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Treatment with semaglutide resulted in up-regulation of GLP-1R expression suggesting a feed-back loop upon activation of the receptor.</data>
    </edge>
    <edge source="PDF_5_Result_860370958687953436" target="Protein_CREB">
      <data key="d8">MENTIONS</data>
      <data key="d9">The level of CREB mRNA was reduced in untreated Pla2g6¯¹- mice and normalised in the high-dose semaglutide-treated group.</data>
    </edge>
    <edge source="PDF_5_Result_860370958687953436" target="Gene_PLA2G6">
      <data key="d8">MENTIONS</data>
      <data key="d9">The level of CREB mRNA was reduced in untreated Pla2g6¯¹- mice and normalised in the high-dose semaglutide-treated group.</data>
    </edge>
    <edge source="PDF_5_Result_860370958687953436" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The level of CREB mRNA was reduced in untreated Pla2g6¯¹- mice and normalised in the high-dose semaglutide-treated group.</data>
    </edge>
    <edge source="PDF_5_Result_-8661222603736243328" target="Protein_BCL-2">
      <data key="d8">MENTIONS</data>
      <data key="d9">Our study demonstrates the presence of apoptosis through modulation of BCl-2 family members, which was largely reversed by semaglutide treatment.</data>
    </edge>
    <edge source="PDF_5_Result_-8661222603736243328" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Our study demonstrates the presence of apoptosis through modulation of BCl-2 family members, which was largely reversed by semaglutide treatment.</data>
    </edge>
    <edge source="PDF_5_Result_-8661222603736243328" target="Process_APOPTOSIS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Our study demonstrates the presence of apoptosis through modulation of BCl-2 family members, which was largely reversed by semaglutide treatment.</data>
    </edge>
    <edge source="PDF_5_Result_426357961769712333" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">This upregulation was reduced following treatment with the GLP-1R agonist.</data>
    </edge>
    <edge source="PDF_5_Result_7791270865785449861" target="Protein_GLP-1R">
      <data key="d8">MENTIONS</data>
      <data key="d9">Treatment with the GLP-1R agonist affects the transcriptional regulation of GSK3ẞ resulting in significant reduction and normalisation to wild-type levels.</data>
    </edge>
    <edge source="PDF_5_Result_7791270865785449861" target="Protein_GSK3ẞ">
      <data key="d8">MENTIONS</data>
      <data key="d9">Treatment with the GLP-1R agonist affects the transcriptional regulation of GSK3ẞ resulting in significant reduction and normalisation to wild-type levels.</data>
    </edge>
    <edge source="PDF_5_Conclusion_-1586288735173776015" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Here, we demonstrate that 0.5 µg/g semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
    </edge>
    <edge source="PDF_5_Conclusion_-1586288735173776015" target="Disease_INAD">
      <data key="d8">MENTIONS</data>
      <data key="d9">Here, we demonstrate that 0.5 µg/g semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
    </edge>
    <edge source="PDF_5_Conclusion_8037783431905148000" target="Compound_SEMAGLUTIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide represents a new potential therapeutic agent that could decelerate disease progression and potentially improve the patient's quality of life.</data>
    </edge>
    <edge source="PDF_5_Conclusion_8037783431905148000" target="Disease_INAD">
      <data key="d8">MENTIONS</data>
      <data key="d9">Semaglutide represents a new potential therapeutic agent that could decelerate disease progression and potentially improve the patient's quality of life.</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-6774985175915621860">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-2999995781462909448">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-4502596496072044522">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_8026474705881486032">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_2359535798452715126">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_2916758855844091943">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_420969686020344714">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-7897340407270493618">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_7630098172249293658">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-4869032256513921850">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_1263465287594110931">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-6268527559379590944">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-5981291692107001170">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_6793792303088618948">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_4000149532510856180">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_625662708329867935">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-7422617096255101567">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_8073815806234392537">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_3951732065118766371">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_3258887076067917652">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_449362107409668405">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_8502938962552273800">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-7336713307888196122">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_7754024338876440667">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-2116604159937777599">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-1856213236509705757">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_-1676962246853325250">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Result_1247314472091141845">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Method_2731279007154695014">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Method_775100123491143823">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Method_-6133997904598456722">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12" target="PDF_12_Conclusion_596753725548238670">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_12_Result_-6774985175915621860" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol is a centrally acting analgesic that has been shown to be effective in a variety of acute and chronic pain states.</data>
    </edge>
    <edge source="PDF_12_Result_-2999995781462909448" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol exerts a dual action by binding to the opioid receptor site in the central nervous system and by weakly inhibiting the reuptake of biogenic amines.</data>
    </edge>
    <edge source="PDF_12_Result_-4502596496072044522" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration.</data>
    </edge>
    <edge source="PDF_12_Result_8026474705881486032" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol would appear to be particularly useful in the elderly population affected by osteoarthritis because, unlike nonsteroidal anti-inflammatory drugs, it does not aggravate hypertension or congestive heart failure, nor does it have the potential to cause peptic ulcer disease.</data>
    </edge>
    <edge source="PDF_12_Result_8026474705881486032" target="Disease_OSTEOARTHRITIS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol would appear to be particularly useful in the elderly population affected by osteoarthritis because, unlike nonsteroidal anti-inflammatory drugs, it does not aggravate hypertension or congestive heart failure, nor does it have the potential to cause peptic ulcer disease.</data>
    </edge>
    <edge source="PDF_12_Result_2359535798452715126" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Compared with narcotics, tramadol does not induce significant respiratory depression, constipation, or have significant abuse potential.</data>
    </edge>
    <edge source="PDF_12_Result_2916758855844091943" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol binds to the u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
    </edge>
    <edge source="PDF_12_Result_420969686020344714" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action</data>
    </edge>
    <edge source="PDF_12_Result_420969686020344714" target="Compound_NALOXONE">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action</data>
    </edge>
    <edge source="PDF_12_Result_-7897340407270493618" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol has definite selectivity for the u opioid receptor compared with the 8 and к opioid receptors.</data>
    </edge>
    <edge source="PDF_12_Result_7630098172249293658" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The pharmacokinetic profile of oral tramadol reflects its 75% bioavailability (rising to 100% with multiple administration), which is not significantly altered when the drug is administered with food.</data>
    </edge>
    <edge source="PDF_12_Result_-4869032256513921850" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Respiratory depression is uncommon with tramadol administration and has occurred only when the recommended dose has been considerably exceeded (overdose) or in conjunction with drugs that themselves depress respiration.</data>
    </edge>
    <edge source="PDF_12_Result_1263465287594110931" target="Disease_OSTEOARTHRITIS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Regular administration seems to be more efficacious for the management of painful osteoarthritis</data>
    </edge>
    <edge source="PDF_12_Result_-6268527559379590944" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The effect of tramadol on the plasma concentration of monoamine oxidase (MAO) inhibitors has not been studied.</data>
    </edge>
    <edge source="PDF_12_Result_-5981291692107001170" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Clinically, coadministration of tramadol with NSAIDs has produced additive analgesic effects, and in animal models clear synergy has been found between tramadol and a number of NSAIDs</data>
    </edge>
    <edge source="PDF_12_Result_6793792303088618948" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol at the usual doses has rarely been associated with respiratory depression</data>
    </edge>
    <edge source="PDF_12_Result_4000149532510856180" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg</data>
    </edge>
    <edge source="PDF_12_Result_4000149532510856180" target="Compound_CODEINE">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg</data>
    </edge>
    <edge source="PDF_12_Result_625662708329867935" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol provided analgesia comparable to that of the reference agents, although there were no statistically significant differences between the treatment groups</data>
    </edge>
    <edge source="PDF_12_Result_-7422617096255101567" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Significantly more tramadol-treated patients completed the study. An average daily dosage of 245mg was significantly more effective than placebo in reducing the severity of the pain at rest.</data>
    </edge>
    <edge source="PDF_12_Result_8073815806234392537" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine.</data>
    </edge>
    <edge source="PDF_12_Result_8073815806234392537" target="Compound_PENTAZOCINE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine.</data>
    </edge>
    <edge source="PDF_12_Result_3951732065118766371" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol was more effective in terms of morning stiffness and the need for concomitant paracetamol.</data>
    </edge>
    <edge source="PDF_12_Result_3951732065118766371" target="Compound_PARACETAMOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol was more effective in terms of morning stiffness and the need for concomitant paracetamol.</data>
    </edge>
    <edge source="PDF_12_Result_3258887076067917652" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
    </edge>
    <edge source="PDF_12_Result_3258887076067917652" target="Compound_DEXTROPROPOXYPHENE">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
    </edge>
    <edge source="PDF_12_Result_449362107409668405" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">both drugs showed comparable efficacy after 4 weeks. The mean daily dose of tramadol was 164.8mg and that of diclofenac was 86.9mg.</data>
    </edge>
    <edge source="PDF_12_Result_449362107409668405" target="Compound_DICLOFENAC">
      <data key="d8">MENTIONS</data>
      <data key="d9">both drugs showed comparable efficacy after 4 weeks. The mean daily dose of tramadol was 164.8mg and that of diclofenac was 86.9mg.</data>
    </edge>
    <edge source="PDF_12_Result_8502938962552273800" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">a mean daily tramadol dose of 160mg (maximum total dose of 400mg) for up to 4 weeks produced overall ‘satisfactory' pain relief in approximately 86% of patients</data>
    </edge>
    <edge source="PDF_12_Result_-7336713307888196122" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis, apparently because the degree of inflammation is not great.</data>
    </edge>
    <edge source="PDF_12_Result_-7336713307888196122" target="Disease_OSTEOARTHRITIS">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol can be effectively substituted for NSAIDs in some patients with osteoarthritis, apparently because the degree of inflammation is not great.</data>
    </edge>
    <edge source="PDF_12_Result_-2116604159937777599" target="Compound_PARACETAMOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">the incidence of dizziness (6.8%), nausea (10.3%), constipation (6.8%) or somnolence (6.0%) was not appreciably different from that with paracetamol plus codeine or aspirin plus codeine</data>
    </edge>
    <edge source="PDF_12_Result_-2116604159937777599" target="Compound_CODEINE">
      <data key="d8">MENTIONS</data>
      <data key="d9">the incidence of dizziness (6.8%), nausea (10.3%), constipation (6.8%) or somnolence (6.0%) was not appreciably different from that with paracetamol plus codeine or aspirin plus codeine</data>
    </edge>
    <edge source="PDF_12_Result_-2116604159937777599" target="Compound_ASPIRIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">the incidence of dizziness (6.8%), nausea (10.3%), constipation (6.8%) or somnolence (6.0%) was not appreciably different from that with paracetamol plus codeine or aspirin plus codeine</data>
    </edge>
    <edge source="PDF_12_Result_-1856213236509705757" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Tramadol produces effects similar to those of an opioid, yet the development of tolerance has been reported to be relatively mild, and symptoms of withdrawal, when present, are not considered to be as severe as those produced by other opioids.</data>
    </edge>
    <edge source="PDF_12_Result_-1676962246853325250" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tolerance to the analgesic effect of tramadol after repeated administration was minimal and less than that produced by morphine</data>
    </edge>
    <edge source="PDF_12_Result_-1676962246853325250" target="Compound_MORPHINE">
      <data key="d8">MENTIONS</data>
      <data key="d9">tolerance to the analgesic effect of tramadol after repeated administration was minimal and less than that produced by morphine</data>
    </edge>
    <edge source="PDF_12_Result_1247314472091141845" target="Compound_PARACETAMOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Paracetamol is a reasonable first-line approach because of the excellent benefit/risk/cost ratio. If low dose intermittent ibuprofen, in over-the-counter dosages, can be used with good pain relief, then there is no good reason to use tramadol. However, if ibuprofen is not sufficiently efficacious, or produces adverse effects, or if the patient has a relative or absolute contraindication, then tramadol can be used, especially if the patient has failed to respond to paracetamol.</data>
    </edge>
    <edge source="PDF_12_Result_1247314472091141845" target="Compound_IBUPROFEN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Paracetamol is a reasonable first-line approach because of the excellent benefit/risk/cost ratio. If low dose intermittent ibuprofen, in over-the-counter dosages, can be used with good pain relief, then there is no good reason to use tramadol. However, if ibuprofen is not sufficiently efficacious, or produces adverse effects, or if the patient has a relative or absolute contraindication, then tramadol can be used, especially if the patient has failed to respond to paracetamol.</data>
    </edge>
    <edge source="PDF_12_Result_1247314472091141845" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Paracetamol is a reasonable first-line approach because of the excellent benefit/risk/cost ratio. If low dose intermittent ibuprofen, in over-the-counter dosages, can be used with good pain relief, then there is no good reason to use tramadol. However, if ibuprofen is not sufficiently efficacious, or produces adverse effects, or if the patient has a relative or absolute contraindication, then tramadol can be used, especially if the patient has failed to respond to paracetamol.</data>
    </edge>
    <edge source="PDF_12_Method_2731279007154695014" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol is a single-entity, centrally acting analgesic</data>
    </edge>
    <edge source="PDF_12_Method_775100123491143823" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol binds to the u opioid receptor site in the central nervous system</data>
    </edge>
    <edge source="PDF_12_Method_-6133997904598456722" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">tramadol inhibits the uptake of noradrenaline and serotonin</data>
    </edge>
    <edge source="PDF_12_Conclusion_596753725548238670" target="Compound_TRAMADOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The availability of tramadol as an analgesic for the management of painful osteoarthritis represents a desirable therapeutic option.</data>
    </edge>
    <edge source="PDF_12_Conclusion_596753725548238670" target="Disease_OSTEOARTHRITIS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The availability of tramadol as an analgesic for the management of painful osteoarthritis represents a desirable therapeutic option.</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_4197650708690233955">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_354537486303178723">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_4184705004567467970">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-6784970168649026019">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-260179632625917423">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_4774744813425608663">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_4733928251773593198">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_4631797196767407880">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-754730249218087050">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-7987352542641189223">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_3767974454484220477">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-5841757439011772607">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_1200982518153901137">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-731215718995173322">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_5198197461515115468">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-6976160984899220301">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-7431969788317810718">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_7019794477971046434">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-8011367986389430369">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_3350740205061296852">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-8402194948833182832">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-2181958032508705436">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_314771194671321701">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_5662459425840310734">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-2258662557350811308">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_8781159825379823151">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_7306967139259324869">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-2315276413657724531">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-7034928497063358712">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-4852487533400575008">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-722433886058403238">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-1703645322827346362">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-5211224457821964713">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-3032712515991033099">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-7933965937644750635">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_596902998640378349">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_5632794443878813450">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_3716971167368789496">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_7798179061516336174">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_2437633947455976786">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_2488598613310986279">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_1730786705567194330">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-2949242152273853589">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-3828702804889172736">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-3686212452926226249">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_3737680705182362017">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_7094012108776873411">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_6553828478640136841">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_7687329608720779505">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-2815337949325978627">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_8498915914996141537">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_-7769707290918879568">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11" target="PDF_11_Result_8525444708222209317">
      <data key="d8">CONTAINS</data>
    </edge>
    <edge source="PDF_11_Result_4197650708690233955" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_4197650708690233955" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_354537486303178723" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Those patients who do not respond adequately to monotherapy with perindopril usually respond with the addition of a second agent, such as a thiazide diuretic.</data>
    </edge>
    <edge source="PDF_11_Result_4184705004567467970" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_4184705004567467970" target="Compound_CAPTOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_4184705004567467970" target="Compound_ATENOLOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_4184705004567467970" target="Compound_HYDROCHLOROTHIAZIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_4184705004567467970" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is at least as effective and as well tolerated as usual therapeutic dosages of captopril, atenolol or hydrochlorothiazide plus amiloride in mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-6784970168649026019" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-6784970168649026019" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-6784970168649026019" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-260179632625917423" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is likely to represent a useful alternative to other members of the ACE inhibitor class in all grades of hypertension and congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-260179632625917423" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is likely to represent a useful alternative to other members of the ACE inhibitor class in all grades of hypertension and congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-260179632625917423" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is likely to represent a useful alternative to other members of the ACE inhibitor class in all grades of hypertension and congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_4774744813425608663" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
    </edge>
    <edge source="PDF_11_Result_4774744813425608663" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
    </edge>
    <edge source="PDF_11_Result_4774744813425608663" target="Protein_ANGIOTENSIN II">
      <data key="d8">MENTIONS</data>
      <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
    </edge>
    <edge source="PDF_11_Result_4733928251773593198" target="Protein_ANGIOTENSIN II">
      <data key="d8">MENTIONS</data>
      <data key="d9">Inhibition of angiotensin II formation, in particular in the vasculature, is the primary pharmacological action of perindopril, leading to a reduction in peripheral vascular resistance with no significant change in heart rate.</data>
    </edge>
    <edge source="PDF_11_Result_4733928251773593198" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Inhibition of angiotensin II formation, in particular in the vasculature, is the primary pharmacological action of perindopril, leading to a reduction in peripheral vascular resistance with no significant change in heart rate.</data>
    </edge>
    <edge source="PDF_11_Result_4631797196767407880" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_4631797196767407880" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-754730249218087050" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
    </edge>
    <edge source="PDF_11_Result_-754730249218087050" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
    </edge>
    <edge source="PDF_11_Result_-7987352542641189223" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-7987352542641189223" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_3767974454484220477" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril is rapidly absorbed, reaching peak plasma concentrations about 1 hour after a single oral dose, and is cleared from the circulation in about 6 hours.</data>
    </edge>
    <edge source="PDF_11_Result_-5841757439011772607" target="Compound_PERINDOPRILAT">
      <data key="d8">MENTIONS</data>
      <data key="d9">Only about 17 to 20% of the orally administered dose is available as perindoprilat, as extensive metabolism to other inactive metabolites occurs.</data>
    </edge>
    <edge source="PDF_11_Result_1200982518153901137" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The use of perindopril in potentially at-risk hypertensive patients, such as the elderly and those with diabetes or renal impairment, has not been associated with any unfavourable metabolic changes.</data>
    </edge>
    <edge source="PDF_11_Result_1200982518153901137" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">The use of perindopril in potentially at-risk hypertensive patients, such as the elderly and those with diabetes or renal impairment, has not been associated with any unfavourable metabolic changes.</data>
    </edge>
    <edge source="PDF_11_Result_1200982518153901137" target="Disease_DIABETES">
      <data key="d8">MENTIONS</data>
      <data key="d9">The use of perindopril in potentially at-risk hypertensive patients, such as the elderly and those with diabetes or renal impairment, has not been associated with any unfavourable metabolic changes.</data>
    </edge>
    <edge source="PDF_11_Result_-731215718995173322" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
    </edge>
    <edge source="PDF_11_Result_-731215718995173322" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
    </edge>
    <edge source="PDF_11_Result_5198197461515115468" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_5198197461515115468" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-6976160984899220301" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-6976160984899220301" target="Compound_CAPTOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-6976160984899220301" target="Compound_ATENOLOL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-6976160984899220301" target="Compound_HYDROCHLOROTHIAZIDE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-6976160984899220301" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-7431969788317810718" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_-7431969788317810718" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
    </edge>
    <edge source="PDF_11_Result_7019794477971046434" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
    </edge>
    <edge source="PDF_11_Result_7019794477971046434" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
    </edge>
    <edge source="PDF_11_Result_-8011367986389430369" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril, a new member of this drug class, is chemically related to enalapril</data>
    </edge>
    <edge source="PDF_11_Result_-8011367986389430369" target="Compound_ENALAPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril, a new member of this drug class, is chemically related to enalapril</data>
    </edge>
    <edge source="PDF_11_Result_3350740205061296852" target="Compound_CAPTOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
    </edge>
    <edge source="PDF_11_Result_3350740205061296852" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
    </edge>
    <edge source="PDF_11_Result_3350740205061296852" target="Compound_ENALAPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
    </edge>
    <edge source="PDF_11_Result_3350740205061296852" target="Compound_PERINDOPRILAT">
      <data key="d8">MENTIONS</data>
      <data key="d9">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
    </edge>
    <edge source="PDF_11_Result_3350740205061296852" target="Compound_ENALAPRILAT">
      <data key="d8">MENTIONS</data>
      <data key="d9">Unlike captopril, both perindopril and enalapril are prodrugs that require hydrolysis to form their respective active metabolites, perindoprilat and enalaprilat.</data>
    </edge>
    <edge source="PDF_11_Result_-8402194948833182832" target="Compound_PERINDOPRILAT">
      <data key="d8">MENTIONS</data>
      <data key="d9">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
    </edge>
    <edge source="PDF_11_Result_-8402194948833182832" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
    </edge>
    <edge source="PDF_11_Result_-2181958032508705436" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-2181958032508705436" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-2181958032508705436" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_-2181958032508705436" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals, healthy human subjects, hypertensive patients and patients with congestive heart failure.</data>
    </edge>
    <edge source="PDF_11_Result_314771194671321701" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
    </edge>
    <edge source="PDF_11_Result_314771194671321701" target="Protein_ANGIOTENSIN II">
      <data key="d8">MENTIONS</data>
      <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
    </edge>
    <edge source="PDF_11_Result_314771194671321701" target="Protein_ANGIOTENSIN I">
      <data key="d8">MENTIONS</data>
      <data key="d9">As a consequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
    </edge>
    <edge source="PDF_11_Result_5662459425840310734" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Human studies have indicated that the maximal ACE inhibitory response to orally ad- ministered perindopril is attained with a single 8 to 16mg dose; ACE inhibition occurs with an onset 1 hour after administration, reaches a maximum at about 4 to 8 hours, and is maintained for 24 hours.</data>
    </edge>
    <edge source="PDF_11_Result_5662459425840310734" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Human studies have indicated that the maximal ACE inhibitory response to orally ad- ministered perindopril is attained with a single 8 to 16mg dose; ACE inhibition occurs with an onset 1 hour after administration, reaches a maximum at about 4 to 8 hours, and is maintained for 24 hours.</data>
    </edge>
    <edge source="PDF_11_Result_-2258662557350811308" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
    </edge>
    <edge source="PDF_11_Result_-2258662557350811308" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands</data>
    </edge>
    <edge source="PDF_11_Result_8781159825379823151" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
    </edge>
    <edge source="PDF_11_Result_8781159825379823151" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
    </edge>
    <edge source="PDF_11_Result_8781159825379823151" target="Compound_PERINDOPRILAT">
      <data key="d8">MENTIONS</data>
      <data key="d9">administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
    </edge>
    <edge source="PDF_11_Result_7306967139259324869" target="Gene_ACE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
    </edge>
    <edge source="PDF_11_Result_7306967139259324869" target="Compound_CAPTOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
    </edge>
    <edge source="PDF_11_Result_7306967139259324869" target="Compound_ENALAPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
    </edge>
    <edge source="PDF_11_Result_7306967139259324869" target="Protein_BRADYKININ">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
    </edge>
    <edge source="PDF_11_Result_7306967139259324869" target="Compound_PROSTAGLANDINS">
      <data key="d8">MENTIONS</data>
      <data key="d9">The ACE inhibitors captopril and enalapril affect the kallikrein-kinin-prostaglandin system, increasing levels of endogenous vasoactive bradykinin and prostaglandins.</data>
    </edge>
    <edge source="PDF_11_Result_-2315276413657724531" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
    </edge>
    <edge source="PDF_11_Result_-2315276413657724531" target="Protein_RENIN">
      <data key="d8">MENTIONS</data>
      <data key="d9">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
    </edge>
    <edge source="PDF_11_Result_-7034928497063358712" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
    </edge>
    <edge source="PDF_11_Result_-7034928497063358712" target="Protein_ATRIAL NATRIURETIC FACTOR">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
    </edge>
    <edge source="PDF_11_Result_-7034928497063358712" target="Disease_MYOCARDIAL INFARCTION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
    </edge>
    <edge source="PDF_11_Result_-4852487533400575008" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
    </edge>
    <edge source="PDF_11_Result_-4852487533400575008" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
    </edge>
    <edge source="PDF_11_Result_-722433886058403238" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals</data>
    </edge>
    <edge source="PDF_11_Result_-722433886058403238" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals</data>
    </edge>
    <edge source="PDF_11_Result_-1703645322827346362" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril was more potent weight-for-weight than enalapril</data>
    </edge>
    <edge source="PDF_11_Result_-1703645322827346362" target="Compound_ENALAPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril was more potent weight-for-weight than enalapril</data>
    </edge>
    <edge source="PDF_11_Result_-5211224457821964713" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
    </edge>
    <edge source="PDF_11_Result_-5211224457821964713" target="Compound_NITRENDIPINE">
      <data key="d8">MENTIONS</data>
      <data key="d9">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
    </edge>
    <edge source="PDF_11_Result_-5211224457821964713" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
    </edge>
    <edge source="PDF_11_Result_-3032712515991033099" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
    </edge>
    <edge source="PDF_11_Result_-3032712515991033099" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
    </edge>
    <edge source="PDF_11_Result_-7933965937644750635" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
    </edge>
    <edge source="PDF_11_Result_-7933965937644750635" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
    </edge>
    <edge source="PDF_11_Result_596902998640378349" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Perindopril in- hibited and even prevented development of card- iac hypertrophy in the rat</data>
    </edge>
    <edge source="PDF_11_Result_5632794443878813450" target="Disease_MYOCARDIAL INFARCTION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias.</data>
    </edge>
    <edge source="PDF_11_Result_5632794443878813450" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias.</data>
    </edge>
    <edge source="PDF_11_Result_3716971167368789496" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Long term perindopril administra- tion either prevented or inhibited development of experimental cardiac hypertrophy</data>
    </edge>
    <edge source="PDF_11_Result_7798179061516336174" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Furthermore, perindopril normalised ex- perimentally induced prolongation of the action potential</data>
    </edge>
    <edge source="PDF_11_Result_2437633947455976786" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Acute administration of perindopril shortly before coronary artery ligation in vivo significantly re- duced mortality and the severity of ventricular tachycardia and fibrillation</data>
    </edge>
    <edge source="PDF_11_Result_2488598613310986279" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Oral administration of single or repeated once daily doses of perindopril 1 to 16mg to normoten- sive subjects either had no significant effect on blood pressure or caused a slight, but significant, blood pressure decrease, particularly with higher doses</data>
    </edge>
    <edge source="PDF_11_Result_1730786705567194330" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Ajayi et al. (1986) found that a single oral dose of perindopril 8mg did not affect blood pressure and heart rate responses to dynamic exercise, fore- arm isometric exercise, the cold pressor test or Val- salva's manoeuvre, but enhanced the vagally me- diated sinus arrhythmia associated with deep breathing.</data>
    </edge>
    <edge source="PDF_11_Result_-2949242152273853589" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Single oral doses of perindopril 4, 8 and 16mg caused a dose-depend- ent increase in brachial and carotid artery diameter and blood flow with a decrease in forearm vascular resistance, as measured by the pulsed Doppler technique.</data>
    </edge>
    <edge source="PDF_11_Result_-3828702804889172736" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
    </edge>
    <edge source="PDF_11_Result_-3828702804889172736" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
    </edge>
    <edge source="PDF_11_Result_-3686212452926226249" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">West et al. (1989) confirmed a perindopril-in- duced increase in parasympathetic tone in patients with essential hypertension, an effect which has also been noted in healthy subjects</data>
    </edge>
    <edge source="PDF_11_Result_-3686212452926226249" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">West et al. (1989) confirmed a perindopril-in- duced increase in parasympathetic tone in patients with essential hypertension, an effect which has also been noted in healthy subjects</data>
    </edge>
    <edge source="PDF_11_Result_3737680705182362017" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
    </edge>
    <edge source="PDF_11_Result_3737680705182362017" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
    </edge>
    <edge source="PDF_11_Result_7094012108776873411" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring</data>
    </edge>
    <edge source="PDF_11_Result_7094012108776873411" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring</data>
    </edge>
    <edge source="PDF_11_Result_7687329608720779505" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The blood pressure response to a single oral dose of perindopril 2mg has been compared with that of enalapril 2.5mg or captopril 6.25mg in a ran- domised double-blind study in 48 elderly patients with chronic cardiac failure</data>
    </edge>
    <edge source="PDF_11_Result_7687329608720779505" target="Compound_ENALAPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The blood pressure response to a single oral dose of perindopril 2mg has been compared with that of enalapril 2.5mg or captopril 6.25mg in a ran- domised double-blind study in 48 elderly patients with chronic cardiac failure</data>
    </edge>
    <edge source="PDF_11_Result_7687329608720779505" target="Compound_CAPTOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The blood pressure response to a single oral dose of perindopril 2mg has been compared with that of enalapril 2.5mg or captopril 6.25mg in a ran- domised double-blind study in 48 elderly patients with chronic cardiac failure</data>
    </edge>
    <edge source="PDF_11_Result_7687329608720779505" target="Disease_HEART FAILURE">
      <data key="d8">MENTIONS</data>
      <data key="d9">The blood pressure response to a single oral dose of perindopril 2mg has been compared with that of enalapril 2.5mg or captopril 6.25mg in a ran- domised double-blind study in 48 elderly patients with chronic cardiac failure</data>
    </edge>
    <edge source="PDF_11_Result_-2815337949325978627" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
    </edge>
    <edge source="PDF_11_Result_-2815337949325978627" target="Compound_CAPTOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
    </edge>
    <edge source="PDF_11_Result_-2815337949325978627" target="Compound_ENALAPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
    </edge>
    <edge source="PDF_11_Result_8498915914996141537" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
    </edge>
    <edge source="PDF_11_Result_8498915914996141537" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
    </edge>
    <edge source="PDF_11_Result_-7769707290918879568" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
    </edge>
    <edge source="PDF_11_Result_-7769707290918879568" target="Disease_HYPERTENSION">
      <data key="d8">MENTIONS</data>
      <data key="d9">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
    </edge>
    <edge source="PDF_11_Result_8525444708222209317" target="Compound_PERINDOPRIL">
      <data key="d8">MENTIONS</data>
      <data key="d9">After administration of a single oral dose of per- indopril 8mg to 11 healthy subjects, 24-hour ur- inary output of sodium and chloride were in- creased by about 25% (p &lt; 0.02) and their renal clearance</data>
    </edge>
  </graph>
</graphml>
